

10 YEARS OF
carē

ANNUAL REPORT 2021-22



Dear Shareholders,

As the world recalibrates itself to the new normal and overall industry starts to see some resurgent tailwinds, importance of timely access to quality healthcare remains a firmly entrenched belief & need across the spectrum of populace – with India being no exception to this imperative. Consequently, this has led to enhanced awareness and adoption of personal health insurance as an efficient means to address the financial requirements of emergency or planned healthcare.

In this operating year, your Company has recorded marked progress on all key growth & development parameters, while adhering to its principal tenets of technological evolution, focus on customer satisfaction, quality servicing and capital adequacy. During FY22, Care Health Insurance garnered a Gross Written Premium of Rs 3,947 cr, representing a growth of ~53% from the previous fiscal while maintaining a healthy post tax profit & solvency ratio of Rs. 11.5 crore and 1.85 respectively. Your organization operated at a combined ratio of 103% during one of the most challenging and unprecedented health crisis globally. Your Company is the only health insurer to record a profitable growth this fiscal notwithstanding the fact that the first quarter was acutely impacted by Covid-related claims.

The industry landscape is rife with opportunity as the health insurance sector grew 26% from the previous year, pegging its market size at over Rs.80,000 cr. Your Company, currently the country's second largest standalone health insurer, is poised for the next quantum leap of growth given its state-of-preparedness on critical success parameters. Care Health today is capacitated with over 30 products encompassing group, travel, fixed benefit and indemnity categories, designed to address the varied needs of its customers. It's 18,900+ strong healthcare provider network services over 1,385 locations across country continues to strengthen and deep mine its distribution capabilities through a vast & evolving network of 207 branches that operate in a hub & spoke structure,.

It gives me immense pleasure in sharing that your Company has been conferred awards for India's Best Health Insurance Product and India's Best Health Insurance Agents at the Insurance Alertss Awards 2021.



As a responsible corporate citizen, Care Health has invested in two key education-centric projects as part of its Corporate Social Responsibility. A primary school in the culturally significant village of Nandgaon, Dist. Mathura, Uttar Pradesh and the over century-old, historically-relevant Prem Mahavidyalaya, Mathura, Uttar Pradesh have been chosen for the purpose. The projects entail renovation, refurbishing, upgradation and maintenance of both institutions that will consequently further the objective of enrolment for quality education in their respective communities.

In conclusion, I would certainly like to mention that the 'unto-last mile' entrepreneurship ethos at Care Health is most inspiring. It is my privilege to work with this team that represents some of the finest industry acumen, cross disciplinary knowledge and unparalleled zeal & enthusiasm.

I sincerely thank all our shareholders & stakeholders for their patronage and guidance to the Company.

With best regards,

Dr. Rashmi Saluja
Non –Executive Chairperson



Dear Shareholder,

It gives me great pleasure to present to you our Annual Report for FY 2021-22.

The year gone by has been a momentous year for us all, as we completed 10 years of operations, or as we prefer to refer to it – '10 Years of Care'. Since our inception, we have adhered to one imperative guiding principle, 'the customer lies at the center of all that we do'. It is that very principle of Care which has brought us this far in our ten-year journey. During the decade, the company has posted a 100x growth in revenue from Rs. 39 cr in FY 2012-13 to Rs. 3947 cr in FY 2021-22. We have settled over 30 lakh claims and offer a network of over 19,000 cashless healthcare providers for our customers' convenience.

Taking our mission of Care for customers ahead, we continue to design specialized products to service the need of every segment and offer a bouquet of value-for-money products, which have to pass the filter of 'would we buy it ourselves?'. Our operating processes are aligned to maximize customer convenience and we ensure seamless servicing and claims. These and other initiatives are being rewarded by the continued belief and faith of our customers.

While the customer is at the center of all that we do, we also value every partnership as a building block that fortifies this enterprise. Mutual respect, progress and transparency are the cornerstones of our cherished partnerships and we believe that it is our symbiotic exchange of ideas that enable us to tap into better growth opportunities, together. As we live in a digital world, to stay ahead we continue to invest in progressive technology to develop future-ready solutions, geared to deliver convenience and efficiency. Accordingly, we have equipped ourselves with automated information exchange, for real-time transfer of information between customer and healthcare provider.

The most valuable foundation on which we build our progress has been, and will continue to be, our respect for our employees. We identify individuals who are a cultural fit for the organization and once they are on-boarded, we nurture them with opportunities for personal and professional growth to achieve their true potential, while ensuring that their concerns and anxieties, if any, are addressed proactively.

I take this opportunity to thank each of our shareholders personally for being a part of our evolution and progress this far. We look forward to your continued support and confidence in the company in the years ahead.

As always, I wish you and your family good health and happiness.

Warmly,

Anuj Gulati
Managing Director & CEO



Care Health Insurance Limited

Contents

Director's Report	1
Auditor's Report	67
Financials	78

DIRECTOR'S REPORT

Dear Members,

Care Health Insurance Limited (*formerly Religare Health Insurance Company Limited*)

Your Directors have the pleasure of presenting the 15th Annual Report together with Audited Financial Statements of the Company for the financial year ended March 31, 2022.

FINANCIAL RESULTS



Particulars	(Rs. in Crores)	
	2021-22	2020-21
Gross Written Premium	3,947.44	2,588.02
Net Written Premium	3,088.42	1,980.83
Net Earned Premium (A)	2,510.84	1,729.47
Net Incurred Claims (B)	1,633.73	953.82
Net Commission (C)	110.17	26.61
Expenses (D)	1,077.92	728.20
Premium Deficiency (E)	(135.88)	111.42
Investment & Other Income (F)	190.65	166.06
Profit / (Loss) Before Tax (A-B-C-D-E+F)	15.55	75.48
Provision for tax	1.84	15.42
Deferred Tax Expense/(Income)	2.21	(42.16)
Profit / (Loss) After Tax	11.50	102.22



HEALTH INSURANCE

INSURANCE PRODUCTS



With awareness and demand of health insurance growing significantly, the industry has realized that a 'one size fits all' approach will not work and therefore your Company has designed specialized products for every segment.

Products	Description
Retail Health Indemnity Products	
carē	A comprehensive Health Insurance plan that addresses an array of healthcare needs, CARE, has been our flagship product since inception. What makes it popular is the flexibility to choose your cover from a range of optional benefits, as per your requirements.
carē advantage	A Comprehensive Health Insurance that provides higher Sum insured options at affordable premiums.
carē freedom	A comprehensive Health Insurance Plan for senior citizens and individuals with pre-existing medical conditions. It is offered without pre-policy medical check-ups and there is no loading based on the individual's health condition.
carē heart	Specifically designed for persons with a pre-existing heart disease i.e. someone who has undergone a heart surgery in the last 7 years. Doesn't require the proposer to undergo a pre-policy Medical Check-up
super mēdiclaim	Indemnity Coverage for specific critical illnesses and surgeries at highly affordable premiums (Premium Instalment options) with IPD as well as OPD coverage & lifelong renewability.
carē plus	An ideal Comprehensive Health Coverage plan specifically designed for youth. Includes features such as unlimited e - consultations, early bird discount etc
carē classic	Comprehensive Hospitalization cover with zone-based pricing targeting customers of Tier 2 and Tier 3 cities
JōY	A Maternity Health Insurance product specially designed for young couples who are planning a family. While the focus is on maternity related hospitalization, this product also covers any hospitalization during the policy tenure.

enhancē	A Super-Top Health Insurance plan that offers high sum insured option at competitive prices. Enhance is most popular among those who already have a health insurance policy with a lower sum insured, and would want to enhance their sum insured to address future healthcare needs.
Domestic Staff Add-on	Add-on product that offers health coverage to the domestic staff of existing Policyholders of retail Health Products
carē shield add-on	Add-on product which offers protection against inflation, NCB reduction and provides coverage for typically non-payable consumables as well.
Arogya Sanjeevani Policy-Care Health Insurance	Standard retail indemnity product which is simple, affordable and designed to meet customers' basic Insurance Needs.
coronā kavach Care Health Insurance	A standardised short term indemnity health insurance plan designed to safeguard you and your family from COVID-19 treatment expenses. Period of coverage ranges from 3 ½ to 9 ½ months.
covid carē	Indemnity-based health insurance policy that covers individuals & families for COVID-19 related medical expenses.
Group Health Products	
Group carē	With adherence to the belief that human capital is an enterprise's most valuable asset, Group Care spans an array of treatment modalities – from intensive in-patient care to primary healthcare and from maternity related treatment to organ transplantation. With a bouquet of optional services to choose from and customize, Group Care is a straightforward plan designed to offer comprehensive coverage with maximum convenience.
group carē 360°	A comprehensive offering for groups including employer-employee and affinity groups, providing a wide range of benefits on both Fixed Benefit as well as Indemnity basis, while also offering innovative Wellness and Value Added Services.
Group Global carē	A comprehensive Global Insurance product that offers wide range of benefits on Indemnity as well as Fixed Benefit basis to eligible Groups.
Grameen carē	A micro-insurance product, which is a comprehensive Group Health Insurance plan to meet rural India's



HEALTH INSURANCE

	healthcare needs.
Group Credit Protection Product	A highly flexible Group product specially designed for credit protection of loan customers with coverage tenure up to 5 years, offering fixed benefits like critical illness and personal accident as well as health indemnity cover.
Group Arogya Sanjeevani policy- Care Health Insurance	Standard group indemnity product which is simple, affordable and designed to meet customers' basic insurance needs. This product will be offered to employer-employee and affinity groups.
Grameen carē Plus	Group micro-insurance product with a bouquet of optional benefits which offers a comprehensive Health Insurance cover to meet rural India's healthcare needs.
Travel Products	
explorē	A comprehensive International Travel Insurance which covers emergency hospitalization and out-patient treatment, Explore also provides other travel related coverage for events such as delay/loss of baggage, loss of passport, trip cancellation among others.
student explorē	A comprehensive Insurance plan for students studying abroad, Student Explore covers hospitalization as well as out-patient treatment and provides other features such as delay/loss of baggage, loss of passport, trip cancellation, study interruption, sponsor protection among others.
Group explorē	This product provides coverage for emergency care of any illness or injury during overseas travel. Policyholder further has the choice to opt for any of the 38 optional benefits.
Add-on-explorē plus	An add-on offering additional features to existing Group Travel benefits
Fixed Benefit Products	
secure	A Fixed Benefit product against Accidental Death and Disabilities, Secure offers a host of optional benefits like Temporary Total Disability, Common Carrier Mishap, PTD improvement and PPD Improvement etc.
assure	A Fixed Benefit product which provides coverage against 20 major critical illnesses, the key USP for Assure is Zero Day Survival Period. Assure also comes with a Personal Accident cover.
Group secure	A Fixed Benefit product that covers Accidental Death and Disabilities with a customization option.
Saral Suraksha Bima	Standard PA product which is simple, affordable and designed to meet customers' basic requirements for accidental coverage
Group Saral Suraksha Bima	Standard PA product that offers accidental coverage to Employer-Employee and Affinity groups

As the organization grows from strength to strength, the product portfolio has also diversified and now comprises of a comprehensive range of products in the health, critical illness, travel and personal accident categories. With due focus on specialization, your Company has worked towards creating new product categories and enriching existing categories.

BUSINESS PERFORMANCE

In the financial year ended March 2022, our Gross Domestic Premium Income (GDPI) rose to Rs. 3,947 Crores from Rs. 2,588 Crores registering a growth of 52 % over financial year 20-21.

Our Profit After Tax (PAT) for the year decreased to Rs. 90.73 Crores, registering a growth of -89 %. Solvency ratio was at 1.85, one of the highest in the industry and significantly above the minimum regulatory requirement of 1.50x. The combined ratio as on March 31, 2022 is 103%. The Net worth of the Company at the end of financial year March 31, 2022 was Rs. 1,207.37 Crores. The Company has launched a few new products, namely, Care Advantage, Arogya Sanjeevani, Corona Kavach, Covid Care, Group Care 360, Care Shield Add- on, Explore V2. During the last year 50 new branches were opened. There are around 14311 permanent employees in the Company. The agent strength, which is back bone of our distribution, has increased from 1,69,183 to 1,97,806 as compared to last financial year.

FUTURE OUTLOOK



Due to COVID-19 pandemic, the awareness level for health insurance has increased which is also reflected in the industry growth, a trend that is expected to continue in the coming period. In order to achieve growth objectives, your Company plans to focus on increasing its distribution footprint through various Channels such as Agency, Banks, Brokers, Digital etc. and shall further intensify distribution in all these channels through efficient application of technology.



INVESTMENTS

Your Company has made Investments in compliance with IRDAI Investment Regulations and total Assets under management as on 31st March, 2022 stands at Rs. 3,566.54 Crores excluding fair value change account. Further, the total investment portfolio of Rs. 3,566.54 Crores has been bifurcated between Shareholders portfolio of

Rs. 1,106.21 Crores and Policyholders portfolio of Rs. 2,460.33 Crores. The return generated in Shareholder portfolio was 6.1% and in Policyholder portfolio return was 6.7%. Overall 31.52 % of the portfolio has been invested in Sovereign securities. The MTM as on March 31, 2022 was Rs. 18.76 crores. Further, 99.57 % of the portfolio is rated AAA and A1+.



TRANSFER TO RESERVES

Your Company had not transferred any amount towards the reserves and surplus during the financial year 2021-2022. However, the Company has created a reserve for employee stock option expenses amounting to Rs. 3.85 Crores during the financial year 2021-22 and have transferred Rs. 29.80 crores to Securities Premium against the exercise of shares.

SHARE CAPITAL



The authorized share capital of your Company as on March 31, 2022 is Rs. 1300,00,00,000 (Rupees Thirteen Hundred Crores only) divided into 130,00,00,000 equity shares (One Hundred and Thirty Crores only) of Rs. 10/- each (Rupees Ten only).

During the financial year 2021-22, your Company has raised Rs. 153,16,12,173 (Rupees One Hundred and Fifty Three Crores Sixteen Lakhs Twelve Thousand One Hundred and Seventy Three only) (consisting of Rs. 67,52,55,400 as share capital amount and Rs. 85,63,56,773 as premium) by allotting: 6,75,25,540 (Six Crore Seventy Five Lakhs Twenty Five Thousand Five Hundred and Forty only) Equity Shares of Rs. 10 each to ESOP Holders pursuant to the exercise of ESOP options under the CEO Employee Stock Options Scheme and Employee Stock Option Scheme.

The paid up equity share capital of your Company as on March 31, 2022 is Rs. 9,08,56,77,360/- (Rupees Nine Hundred and Eight Crores Fifty Six Lakhs Seventy Seven Thousand Three Hundred and Sixty Only) divided into 90,85,67,736 (Ninety Crores Eighty Five Lakhs Sixty Seven Thousand Seven Hundred and Thirty Six only) equity shares of Rs. 10 each (Rupees Ten only). The Share premium amount in Share premium account as on March 31, 2022 is Rs. 3,29,26,53,690 (Rupees Three Twenty Nine Crore Twenty Six Lakh Fifty Three Thousand Six Hundred and Ninety Only)

ISSUE OF SWEAT EQUITY SHARES

During the financial year, your company has not issued any sweat equity shares.

RURAL & SOCIAL SECTOR OBLIGATION

Your Company has complied with the requirements of the IRDAI Regulations on Rural and Social Sector obligations.

DIVIDEND

Your Company was able to earn a profit after tax of Rs. 11.50 Crores in FY 2021-22. However, the Company has an accumulate losses of Rs. 81.83 Crores as on March 31, 2022 and in accordance with Section 123 of the Companies Act, 2013, the Company cannot distribute dividend unless carried over previous losses and depreciation not provided in previous year or years are set off against profit of the Company for the current year.

The Company is in the growing phase and requires funds for expansion to maintain the minimum prescribed solvency margin.

Considering above Company is not proposing any dividend for the financial year 2021-22.

MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There has been no material change and commitment which will affect the financial position of the Company.

STATEMENT ON THE AFFAIRS OF THE COMPANY



- Section 3A of the Insurance Act, 1938 has been amended by the Insurance Laws (Amendment) Act, 2015 to remove the process of annual renewal of the Certificate of Registration issued to Insurers under Section 3 of the Insurance Act, 1938. However, it has been stated that Insurers shall continue to pay such annual fee as may be prescribed by the Regulations. Insurance Regulatory Development Authority of India ("IRDAI") in line with the above amendment issued a general circular stating that Certificate of Registration of the Insurers renewed in 2014, expiring in March 2015, shall continue to be in force from April 1, 2015 subject to payment of renewal fee. Your Company had paid the renewal fee.
- During its tenth year and ninth full fiscal year of operations, your Company has continued to focus on developing its personnel and management strength, customer-led processes, scalable infrastructure, technology enhancement and distribution capabilities.
- With a bouquet of multiple products across retail and group categories, your Company has products for each segment such as health, personal accident, and critical illness, travel, excess of loss and maternity. Your Company has been servicing across country with network of 208 branches.
- During financial year 2021-22, your Company has under-written premium of Rs. 3,947.44 Crores.
- Your Company has tied up with more than 18,900 healthcare network providers to facilitate cashless services to its customers.
- All retail hospitalisation claims are managed by in-house Claims team except for the travel insurance where the claim is managed through Assistant Service Provider.
- Since the geographical spread of Group policies is vast and also due to customer preference, your Company has tied up with Third Party Administrators to service claims registered against few selective Group policies.

CHANGE IN THE NATURE OF BUSINESS

Your Company has not changed its nature of business during the year.

SUBSIDIARIES/JOINT VENTURES/ASSOCIATES

The Company does not have any subsidiary/ Joint Venture/ Associate Company during the Financial Year 2021-22.

DETAILS OF REVISION OF FINANCIAL STATEMENT OR REPORT

Neither during FY 2021-22 nor in any of the three preceding financial years, the Company has revised its Financial Statement or reports either voluntarily or pursuant to the order of a judicial authority

DIRECTORS



The composition of the Board of Directors of your Company is in conformity with the requirements of Corporate Governance Guidelines issued by IRDAI and the Companies Act, 2013. As on March 31, 2022, the Board of Directors of the Company consists of 11 Directors comprising of a Managing Director & CEO, 3 Non-Executive Directors, 1 Nominee Director and 6 Non-Executive Independent Directors as follows:

Board Composition		
S.No.	Members	Designation
1	Dr. Rashmi Saluja	Non-Executive Chairperson
2	Mrs. Asha Nair	Non-Executive Independent Director
3	Dr. Vijay Shankar Madan	Non-Executive Independent Director
4	Mr. Hamid Ahmed	Non-Executive Independent Director
5	Mr. Malay Kumar Sinha	Non-Executive Independent Director
6	Mr. S. L. Mohan	Non-Executive Independent Director
7	Lt. Gen. (Retd.) S. S. Mehta	Non-Executive Independent Director
8	Mr. Anuj Gulati	Managing Director & CEO
9	Mr. Kartikeya Dhruv Kaji	Non-Executive Director

10	Mr. Sunish Sharma	Non-Executive Director
11	Mr. Chander Mohan Minocha	Bank Nominee Director

During the year, Mr. S. C. Tripathi, Non-Executive Independent Director passed away on May 19, 2021.

Further, during the year, Mr. Sunish Sharma was appointed as an Additional Non-Executive Director on the Board of the Company and as a member of Nomination & Remuneration Committee w.e.f. August 02, 2021. The appointment of Mr. Sunish Sharma was further regularised as Non-Executive Director of the Company as per the provisions of the Companies Act, 2013, in the Annual General Meeting held on September 27, 2021. The Company had received requisite declarations and disclosures under the Companies Act, 2013 and IRDAI Corporate Governance Guidelines from Mr. Sunish Sharma.

Also, the members in the last Annual General Meeting of the Company held on September 27, 2021, approved the appointment of Dr. Rashmi Saluja as director of the Company liable to retire by rotation. The Company had received requisite declarations and disclosures under the Companies Act, 2013 and IRDAI Corporate Governance Guidelines from Dr. Rashmi Saluja.

Further, during the year, in accordance to the approval as received from IRDAI, Mr. Hamid Ahmed and Dr. Vijay Shankar Madan were appointed as the Non-Executive Independent Directors of the Company w.e.f. November 16, 2021 as per the provisions of the Companies Act, 2013 and the IRDAI Guidelines. The Company had received requisite declarations and disclosures under the Companies Act, 2013 and IRDAI Corporate Governance Guidelines from Mr. Hamid Ahmed and Dr. Vijay Shankar Madan.

Furthermore, Mr. Siddharth Dinesh Mehta, Non-Executive Director of the Company resigned from the Board and its various Committees w.e.f. December 31, 2021.

Also, during the year, Mr. Chander Mohan Minocha, Chief General Manager, Treasury & International Banking, Union Bank of India was appointed as Nominee Director on the Board of the Company w.e.f. January 28, 2022, post receipt of approval by IRDAI. The Company had received requisite declarations and disclosures under the Companies Act, 2013 and IRDAI Corporate Governance Guidelines from Mr. Chander Mohan Minocha.

Further, the Company had also received requisite declaration by the Independent Directors of the Company in accordance to Section 149(7) of the Companies Act, 2013 including the declaration relating to registration with Independent Director's Databank, declaration under 149(6) of the Companies Act, 2013 that they meet the criteria of independence and declarations from the directors as required under the Companies Act, 2013 and IRDAI Corporate Governance Guidelines.

COMMITTEES OF THE BOARD

Your Company has constituted following mandatory and non-mandatory Committees as required under the Corporate Governance Guidelines issued by Insurance Regulatory & Development Authority of India (IRDAI).



All decisions pertaining to the constitution of the Board Committees, appointment of members and fixation of Terms of Reference of the Committees are taken by the Board of Directors.

MEETINGS OF THE BOARD AND ITS COMMITTEES



Details of the composition, qualification, field of specialization, status of directorships, meetings held during the financial year 2021-22 and the attendance at each meeting of the Board and its Committees are as under:

BOARD OF DIRECTORS

During the financial year 2021-22, your Company held Four (4) Board Meetings i.e. on June 15, 2021, August 02, 2021, November 01, 2021 and February 03, 2022. The brief details are as under:

S.No.	Name of the Director	Qualification	Field of specialization	Nature of Directorship	Designation in the Committee/ Board	Meeting date 15 th June, 2021	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	MBBS, MD & MBA (Finance)	Doctor Entrepreneur and Academician	Non-Executive Chairperson	Chairperson	Present	Present	Present	Present
2	Mrs. Asha Nair	Economic (Hons), Masters in Social Work, Fellow member of Insurance Institute of India	Insurance Sector	Non-Executive Independent Director	Member	Present	Present	Present	Present



HEALTH INSURANCE

3	Dr. Vijay Shankar Madan** *	IAS	Retired IAS	Non-Executive Independent Director	Member	NA	NA	NA	Present
4	Mr. Hamid Ahmed**	B.A. (Eco.) from Delhi University; M.B.A. from London, U.K.	Business Management	Non-Executive Independent Director	Member	NA	NA	NA	Present
5	Mr. Malay Kumar Sinha	B.A. (Hons), M.A. in Humanities and M. Phil in strategic studies	Retired IPS	Non-Executive Independent Director	Member	Present	Present	Present	Present
6	Mr. Sham Lal Mohan	B.Sc. Mechanical Engg. and AIII (General), Insurance Institute of India, Mumbai	Insurance Sector	Non-Executive Independent Director	Member	Present	Present	Present	Present
7	Lt. Gen. (Retd.) S. S. Mehta	M. Sc. (Defence Studies)	Defence	Non-Executive Independent Director	Member	Present	Present	Present	Present
8	Mr. Anuj Gulati	B. Tech, IIT Delhi, PGDBM, IIM Bangalore	Insurance Sector	Managing Director & CEO	Member	Present	Present	Present	Present
9	Mr. Kartikeya Dhruv Kaji	MBA from The Wharton School of the University of Pennsylvania, Bachelor of Arts in Economics from Dartmouth College, member of the Mumbai chapter of the Entrepreneurs' Organization	Business Management	Non-Executive Director	Member	Present	Present	Present	Present



HEALTH INSURANCE

10	Mr. Sunish Sharma**	MBA, IIM Calcutta, BBA (H), Delhi University, Cost Accountant	Business Management	Non-Executive Director	Member	NA	NA	Present	Present
11	Mr. Chander Mohan Minocha****	B.Com, LLB, MBA, Diploma in Personnel Management and Industrial Relations Certified Associate of Indian Institute of Bankers (CAIIB) Diploma in Treasury Investment and Risk Management from Indian Institute of Banking and Finance	Banking	Bank Nominee Director	Member	NA	NA	NA	Present
12	Mr. Siddharth Dinesh Mehta	Bachelor's degree in Business Management and Finance from King's College, University of London.	Business Management	Non-Executive Director	Member	Absent	Absent	Absent	NA
13	Mr. Sushil Chandra Tripathi*****	MSc (Phy-First class first), LLB, PG Dip in Development (Cantab), AIM A Dip in Management	Retired IAS	Non-Executive Independent Director	Member	NA	NA	NA	NA

*Mr. Siddharth Dinesh Mehta resigned from the Board of Directors w.e.f. December 31, 2021

**Mr. Sunish Sharma was appointed on Board and as a member of Nomination & Remuneration Committee w.e.f. August 02, 2021.

***Dr. Vijay Shankar Madan and Mr. Hamid Ahmed were appointed on the Board of Directors w.e.f. November 16, 2021.

**** Mr. Chander Mohan Minocha was appointed as Bank Nominee Director on the Board of Directors w.e.f. January 28, 2022.

****Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

AUDIT COMMITTEE

Audit Committee has been functioning as per the provisions of the Companies Act, 2013 and the Corporate Governance Guidelines issued by IRDAI. The major role of the Audit Committee is to oversee the financial statements, financial reporting, statement of cash flow; disclosure processes both on an annual and quarterly basis.

During the financial year 21-22, the Committee held four (4) meetings i.e. on-June 14, 2021, August 02, 2021, November 01, 2021 and February 03, 2022. The details of attendees are as under:

Sr. No.	Name of the member	Nature of Directorship Independent / Executive / Non-Executive	Designation in the Committee / Board Chairperson / Member	Meeting dated 14 th June, 2021	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present	Present	Present	Present
2	Mrs. Asha Nair	Non-Executive Independent Director	Member	Present	Present	Present	Present
3	Dr. Vijay Shankar Madan*	Non-Executive Independent Director	Member	NA	NA	NA	Present
4	Mr. Hamid Ahmed*	Non-Executive Independent Director	Member	NA	NA	NA	Present
5	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present	Present	Present	Present
6	Mr. S. L. Mohan	Non-Executive Independent Director	Member	Present	Present	Present	Present
7	Lt. Gen. (Retd.) S. S. Mehta	Non-Executive Independent Director	Member	Present	Present	Present	Present
8	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present	Present	Present	Present
9	Mr. Siddharth Dinesh Mehta**	Non-Executive Director	Member	Present	Absent	Absent	NA
10	Mr. Sushil Chandra Tripathi***	Non-Executive Independent Director	Member	NA	NA	NA	NA

*Appointed as members of the Committee w.e.f. November 16, 2021.

**Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

***Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

INVESTMENT COMMITTEE

The Investment Committee has been functioning in accordance with Corporate Governance Guidelines issued by IRDAI, The Committee's role is to manage the investment out of the policyholders' funds, laying down overall investment policy and operational framework for investment operations of the Company. During the financial year 21-22, the Committee held four (4) meetings i.e. on June 14, 2021, August 02, 2021, November 01, 2021 and February 03, 2022. The details of attendees are as under:

Sr. No.	Name of the member	Nature of Directorship Independent / Executive/ Non-Executive	Designation in the Committee/ Board Chairperson/ Member	Meeting dated 14 th June, 2021	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present	Present	Present	Present
2	Mr. Hamid Ahmed*	Non-Executive Independent Director	Member	NA	NA	NA	Present
3	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present	Present	Present	Present
4	Mr. S. L. Mohan	Non-Executive Independent Director	Member	Present	Present	Present	Present
5	Lt. Gen. (Retd.) S. S. Mehta	Non-Executive Independent Director	Member	Present	Present	Present	Present
6	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present	Present	Present	Present
7	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present	Present	Present	Absent
8	Mr. C. M. Minocha**	Bank Nominee Director	Member	NA	NA	NA	Present
9	Mr. Pankaj Gupta	Chief Financial Officer	Member	Present	Present	Present	Absent
10	Mr. Nitin Katyal	Chief Investment Officer	Member	Present	Present	Present	Absent
11	Mr. Manish	Chief Risk	Member	Present	Present	Present	Present

	Dodeja	Officer					
12	Mr. Irvinder Singh Kohli	Appointed Actuary	Member	Present	Present	Present	Present
13	Mr. Siddharth Dinesh Mehta***	Non-Executive Director	Member	Present	Absent	Absent	NA
14	Mr. Sushil Chandra Tripathi***	Non-Executive Independent Director	Member	NA	NA	NA	NA

* Mr. Hamid Ahmed was appointed as member of the Committee w.e.f. November 16, 2021.

** Mr. C. M. Minocha was appointed as member w.e.f. January 28, 2022.

*** Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

**** Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

RISK MANAGEMENT COMMITTEE

The Risk Management Committee has been functioning in accordance with Corporate Governance Guidelines issued by IRDAI, wherein its major role is to assist the Board in effective operation of the risk management system. During the financial year 21-22, the Committee held four (4) meetings i.e. June 14, 2021, August 02, 2021, November 01, 2021 and February 03, 2022. The details of attendees are as under:

S. No.	Name of the member	Nature of Directorship	Designation in the Committee/ Board	Meeting dated 14 th June, 2021	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present	Present	Present	Present
2	Mr. Hamid Ahmed*	Non-Executive Independent Director	Member	NA	NA	NA	Present
3	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present	Present	Present	Present
4	Mr. S. L. Mohan	Non-Executive Independent Director	Member	Present	Present	Present	Present
5	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present	Present	Present	Present
6	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present	Present	Present	Absent
7	Mr. Siddharth Dinesh	Non-Executive Director	Member	Present	Absent	Absent	NA

	Mehta**						
8	Mr. Sushil Chandra Tripathi***	Non-Executive Independent Director	Member	NA	NA	NA	NA

*Appointed as a member of the Committee w.e.f. November 16, 2021

**Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

*** Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

POLICYHOLDERS PROTECTION COMMITTEE

The Policyholders Protection Committee has been functioning in accordance with Corporate Governance Guidelines issued by IRDAI. The major role of the Committee is to put in place the proper procedures and effective mechanism to address complaints and grievance of policyholders. During the financial year 21-22, the Committee held four (4) meetings i.e. on June 14, 2021, August 02, 2021, November 01, 2021 and February 03, 2022. The details of attendees are as under:

S. No.	Name of the member	Nature of Directorship	Designation in the Committee/ Board	Meeting dated 14 th June, 2021	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present	Present	Present	Present
2	Mrs. Asha Nair	Non-Executive Independent Director	Member	Present	Present	Present	Present
3	Dr. Vijay Shankar Madan*	Non-Executive Independent Director	Member	NA	NA	NA	Present
4	Mr. Hamid Ahmed*	Non-Executive Independent Director	Member	NA	NA	NA	Present
5	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present	Present	Present	Present
6	Lt. Gen. (Retd.) S. S. Mehta	Non-Executive Independent Director	Member	Present	Present	Present	Present
7	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present	Present	Present	Present
8	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present	Present	Present	Absent
9	Mr. Siddharth Dinesh Mehta**	Non-Executive Director	Member	Present	Absent	Absent	NA

10	Mr. Sushil Chandra Tripathi***	Non-Executive Independent Director	Member	NA	NA	NA	NA
11	Mr. S. L. Mohan (Expert Representative)	Non-Executive Independent Director	Expert Representative	Present	Present	Present	Present

*Mr. Hamid Ahmed and Dr. Vijay Shankar Madan were appointed as members of the Committee w.e.f. November 16, 2021.

** Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

*** Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

NOMINATION & REMUNERATION COMMITTEE

Nomination and Remuneration Committee has been functioning pursuant to the Companies Act, 2013 and Corporate Governance Guidelines issued by IRDAI. One of its major roles is to determine the remuneration and compensation packages for the CEO and approve the compensation philosophy for employees of the Company.

Mr. Malay Kumar Sinha is the Chairperson of the Committee. During the financial year 21-22, the Committee held three (3) meetings i.e. on June 14, 2021 (reconvened on June 15, 2021, August 02, 2021, and November 01, 2021. The details of attendees are as under:

Sr. No.	Name of the member	Nature of Directorship Independent / Executive / Non-Executive	Designation in the Committee / Board Chairperson / Member	Meeting dated 14 th June, 15 th June, 2021	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present	Present	Present
2	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Chairperson	Present	Present	Present
3	Mr. S. L. Mohan	Non-Executive Independent Director	Member	Present	Present	Present
4	Lt. Gen. (Retd.) S. S. Mehta	Non-Executive Independent Director	Member	Present	Present	Present
5	Mr. Kartikeya Dhruv Kaji*	Non-Executive Director	Member	Present	Present	NA
6	Mr. Sunish Sharma**	Non-Executive Director	Member	NA	NA	Present

* Mr. Kartikeya Dhruv Kaji stepped down from the Committee w.e.f August 02, 2021

** Mr. Sunish Sharma appointed in the committee w.e.f. August 02, 2021

ALLOTMENT COMMITTEE

The major role of the Committee is to assist the Board in the allotment of shares. During the financial year 21-22, the Committee held three (3) meetings i.e. on August 02, 2021, November 01, 2021 and February 03, 2022. The details of attendees are as under:

S r. N o.	Name of the member	Nature of Directorship Independent/ Executive/ Non- Executive	Designation in the Committee/ Board Chairperson / Member	Meeting dated 2 nd August, 2021	Meeting dated 1 st November, 2021	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present	Present	Present
2	Mr. Hamid Ahmed*	Non-Executive Independent Director	Member	NA	NA	Present
3	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present	Present	Present
4	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present	Present	Present
5	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present	Present	Absent
6	Mr. Siddharth Dinesh Mehta**	Non-Executive Director	Member	Absent	Absent	NA
7	Mr. Sushil Chandra Tripathi***	Non-Executive Independent Director	Member	NA	NA	NA
8	Mr. S. L. Mohan	Non-Executive Independent Director	Member	Present	Present	Present

*Appointed as a member of the Committee w.e.f. November 16, 2021

** Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

*** Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE (CSR)

The major role of the Committee is to overview the CSR activities of the Company which shall focus on promoting consumer awareness and protection, eradicating hunger, poverty and malnutrition, promoting healthcare including preventive healthcare, ensuring environment sustainability and ecological balance, supporting skill development and generation of employment, promoting education across the continuum- primary, secondary and tertiary especially among children, women, elderly and the differently-abled.

During the financial year 21-22, the Committee held one (1) meeting i.e. on June 14, 2021. The details of attendees are as under:

Sr. No.	Name of the member	Nature of Directorship Independent/ Executive/ Non- Executive	Designation in the Committee/ Board Chairperson/ Member	Meeting dated 14 th June, 2021
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present
2	Mr. Hamid Ahmed*	Non-Executive Independent Director	Member	NA
3	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present
4	Lt. Gen. (Retd.) S. S. Mehta	Non-Executive Independent Director	Member	Present
5	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present
6	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present
7	Mr. Siddharth Dinesh Mehta**	Non-Executive Director	Member	Present
8	Mr. Sushil Chandra Tripathi***	Non-Executive Independent Director	Member	NA

*Appointed as a member of the Committee w.e.f. November 16, 2021

** Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

*** Mr. Sushil Chandra Tripathi passed away on May 19, 2021.

INITIAL PUBLIC OFFERING (IPO) COMMITTEE

The major role of the IPO Committee is preparation of the Company's IPO, including selecting and working with underwriters and counsel and preparing & reviewing a registration statement. Also, the Committee shall act in accordance with the Companies Act, 2013 and SEBI (ICDR) Regulations, 2018, other applicable laws, if any and in line with various Agreements executed between various shareholders. During the financial year 21-22, the Committee held one (1) meeting i.e. on June 14, 2021. The details of attendees are as under:

Sr. No.	Name of the member	Nature of Directorship Independent/ Executive/ Non- Executive	Designation in the Committee/ Board Chairperson/ Member	Meeting dated 14 th June, 2021
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present
2	Mr. Hamid Ahmed*	Non-Executive Independent Director	Members	NA
3	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present
4	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present

5	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present
6	Mr. Siddharth Dinesh Mehta**	Non-Executive Director	Member	Present

*Appointed as a member of the Committee w.e.f. November 16, 2021

** Resigned from the Board of Directors and its various Committees w.e.f. December 31, 2021

STAKEHOLDERS RELATIONSHIP COMMITTEE

The major role of the Stakeholders Relationship Committee includes overseeing and reviewing all matters connected with securities of the Company, redressal of Shareholders/ Investors/ Debenture holders/other security holder's complaints/queries and overseeing the performance of the Registrar and Transfer Agent of the Company. Also, the Committee shall act in accordance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, other applicable laws, if any and in line with various Agreements executed between various shareholders. During the financial year 21-22, the Committee held one (1) meeting i.e. on February 03, 2022. The details of attendees are as under:

Sr. No.	Name of the member	Nature of Directorship Independent/ Executive/ Non- Executive	Designation in the Committee/ Board Chairperson/ Member	Meeting dated 3 rd February, 2022
1	Dr. Rashmi Saluja	Non-Executive Chairperson	Member	Present
2	Mr. Malay Kumar Sinha	Non-Executive Independent Director	Member	Present
3	Mr. Anuj Gulati	Managing Director & CEO (Executive Director)	Member	Present
4	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	Member	Present

Apart from the above mentioned Committee meetings, there was also an Independent Director's Meeting held on June 14, 2021 in accordance to the Schedule IV of the Companies Act, 2013.

KEY MANAGERIAL PERSONNEL (KMP)



The Board in its meeting held on April 30, 2014 had designated Mr. Anuj Gulati, Managing Director & CEO, Mr. Pankaj Gupta, Chief Financial Officer and Mr. Pratik Kapoor, Company Secretary as KMPs of the Company in accordance to the Companies Act, 2013.

Further, the Board in its meeting held on July 26, 2016 had designated the following as the KMPs of the Company in accordance with the IRDAI revised Corporate Governance Guidelines:

S.No.	Name of Key Managerial Person (KMP)	Designation
1	Anuj Gulati	Managing Director & CEO
2	Pankaj Gupta	Chief Financial Officer
3	Ajay Shah	Chief Marketing Officer
4	Chandrakant Mishra	Head - Institutional Business
5	Manish Dodeja	Chief Risk Officer
6	Anoop Singh	Chief Compliance Officer
7	Sanjeev Meghani	Head - Human Resources
8	Nitin Katyal	Chief Investment Officer
9	Irvinder Singh Kohli	Appointed Actuary
10	Bhawana Jain	Chief of Internal Audit
11	Pratik Kapoor	Company Secretary



DEPOSITS

Your Company has neither invited nor accepted any deposits from the public during the year under review within the meaning of Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules.



LOANS AND INVESTMENT

The Company had not taken any loans. Also, the Investment has been made in accordance with the Insurance Act, 1938 and prescribed Rules, Regulations and circulars thereunder.

DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

There is no loan in the books of the Company. Hence the aforesaid clause is not applicable to the Company.

RESTRICTIONS ON PURCHASE BY COMPANY OR GIVING LOANS BY IT FOR PURCHASE OF ITS SHARES.



The Company had not provided Loans to any person to purchase or subscribe for fully paid up shares in the Company or its holding Company.

RELATED PARTY TRANSACTIONS



All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions made by the company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large. All Related Party transactions form part of the financials.

CORPORATE SOCIAL RESPONSIBILITY



The Corporate Social Responsibility Policy of the Company as approved by the Board has been made in accordance to the Corporate Governance Guidelines issued by the Insurance Regulatory and Development Authority of India (IRDAI) along with Section 135 of the Companies Act, 2013 and Companies (Corporate Social Responsibility) Rules, 2014.

The Company's CSR activities focus on promoting consumer awareness and protection, eradicating hunger, poverty and malnutrition, promoting healthcare including preventive healthcare, ensuring environment sustainability and ecological balance, supporting skill development and generation of employment, promoting education across the continuum-primary, secondary and tertiary especially among children, women, elderly and the differently-abled.

During the Financial year, your Company has spent CSR funds towards renovation, upgradation and maintenance of primary school in Nandgaon, Dist. Mathura, Uttar Pradesh of about Rs. 0.49 crore including GST and had modified its existing plan to spend the remaining amount of Rs. 0.83 crore including GST on an on-going basis towards the renovation, upgradation and maintenance of Prem Mahavidyalaya, Mathura, Uttar Pradesh in accordance to the CSR policy. The detailed CSR Policy of the Company is available on the website of the Company and can be accessed through the link provided below:

https://cms.careinsurance.com/cms/public/uploads/uploads/other_disclosure/CSR-POLICY_1586761680.pdf

Also, Annual Report on CSR Activities is enclosed herewith as **Annexure - A**

DIRECTOR'S APPOINTMENT POLICY AND POLICY ON REMUNERATION OF DIRECTORS

With regard to the appointment and remuneration of Directors and KMPs of the Company, your Company has formulated the following policies in accordance with the Companies Act, 2013 along with applicable IRDAI Regulations and Guidelines. These Policies are reviewed, updated and approved by the Board from time to time:

- Policy on Directors Appointment – **Annexure - B(i)**
- Policy on Remuneration of Directors – **Annexure - B(ii)**
- KMPs appointment and Remuneration Policy – **Annexure - B(iii)**

The Nomination & Remuneration Committee (NRC) of the Company determines the criteria of appointment to the Board and is vested with the authority to identify candidates for appointment to the Board of Directors. The NRC, along with the Board, on continuous basis will review appropriate skills, characteristics and experience required by the Board as a whole and its individual members.

In evaluating the suitability of individual Board members, the NRC will take into account multiple factors, including general understanding of the business, education, professional background, personal achievements, etc. Few important criteria against which each prospective candidate will also be evaluated are personal and professional ethics, integrity and values.

The NRC will evaluate each prospective candidate with the objective of having a group that best enables the success of the company's business.

The form and amount of director remuneration will be recommended by the NRC to the Board for approval within the maximum amount permissible under the law. Employee directors will not be paid for Board membership in addition to their regular employee compensation.

The NRC will conduct a review of director compensation on a periodic basis to ensure directors of the Company are compensated effectively in a manner consistent with the strategy of the Company, and to further ensure that the Company will be able to attract, retain and reward those who contribute to the success of the Company.

The Board and Committee(s) members in its meeting held on April 26, 2022 evaluated the Board and the Committee(s). Also, in the Board Meeting, the Peer Evaluation was done on April 26, 2022.

VIGIL MECHANISM ESTABLISHED BY THE COMPANY



The Board of Directors in its meeting held on October 31, 2014 adopted the Whistle Blower Policy of the Company. The Chairperson of the Audit Committee is Ombudsman of the Company. The said policy was reviewed from time to time.

Objective of the Policy:

- ✓ The Company is committed to adhere to the highest standards of ethical, moral and legal conduct of business operations. To maintain these standards, the Company encourages disclosures by its stakeholders who have concerns about any suspected misconduct.
- ✓ The disclosures made under this policy could pertain to concerns about possible irregularities, governance weaknesses, financial reporting issues, violation of law, unethical practices or gross misconduct by the employees of the Company that can lead to financial loss and/ or reputational risk to the organization.

The Company had not received any case during FY 2021-22.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT THE WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013



Your Company has formulated the Policy on Prevention of Sexual Harassment at workplace in line with the requirements of The Sexual Harassment of Women at the Work Place (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set-up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under the Policy. The following

is a summary of sexual harassment complaints received and disposed of during the year 2021-22.

- a) No. of complaints received: 4
- b) No. of complaints disposed off: 4

EMPLOYEES STOCK OPTION SCHEME



The details of the Employees Stock Option Scheme of the Company during the financial year 2021-2022 are:

PARTICULARS*	DETAILS
Options granted	2,77,58,288
Options vested	4,43,10,845
Options exercised	6,75,25,540
The total no. of shares arising as a result of exercise of option	6,75,25,540
Options lapsed	63,165
The exercise price	Rs. 10, Rs. 21.85, Rs. 34.31 & Rs. 37.89
Variation of terms of options	12.5% to 15%
Money realized by exercise of options**	67,52,55,400
Total no. of options in force	6,14,51,006 as on March 31, 2022
Employee wise details of options granted:	
(i) Key Managerial Personnel	
Any other employee who receives a grant of options in any one year of option amounting to 5% or more of options granted during that year	NIL
Identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital(excluding outstanding warrants and conversions) of the company at the time of grant.	NIL

* ESOPs issued in FY 2021-22

**excluding premium

AUDITORS



In accordance with the IRDAI Corporate Governance Guidelines issued on May 18, 2016, and Section 139 of Companies Act, 2013, the Company is required to appoint two statutory auditors on a joint basis at a General Meeting who shall hold office from the conclusion of that meeting till the conclusion of the sixth meeting and can be reappointed for maximum two terms of five consecutive years.

The Current Statutory Auditors of the Company i.e. M/s T. R. Chadha & Co. LLP and M/s S. P. Chopra & Co. shall be completing the tenure of 5 years at the forthcoming Annual General Meeting.

In accordance with the guidelines and as per the discussion in the Board meeting, it was proposed to reappoint M/s S. P. Chopra & Co. as one of the Joint Statutory Auditors of the Company for a tenure of 4 years, who retire at the conclusion of the ensuing Annual General Meeting and have confirmed their eligibility and willingness to accept the office of the Statutory Auditors, if re-appointed.

Also, since the tenure of M/s T R Chadha & Co. LLP is going to expire at the ensuing Annual General Meeting as per Companies Act, 2013 and IRDAI CG Guidelines and they cannot be reappointed at the ensuing AGM, the Board in its meeting held on April 26, 2022 has proposed M/s Nangia & Co LLP to be appointed as one of the Joint Auditors of the Company for a tenure of 5 years, and who have confirmed their eligibility and willingness to accept the office of the Statutory Auditors, if appointed.

The Auditors have furnished a certificate of their eligibility for re-appointment under Section 141 of the Companies Act, 2013 and have also provided the declaration in Form A1 as prescribed by the IRDAI Corporate Governance Guidelines indicating their willingness to hold the said office.

FRAUDS REPORTED BY THE AUDITOR

No material fraud was reported by the Auditors of the Company during the financial year 2021-22.

AUDITORS' REPORT



The observations of the Auditors in their report read together with the Notes on Accounts are self-explanatory and therefore, in the opinion of the Directors, do not call for any further explanation. Also, no material fraud was

reported by the Auditors of the Company during the Financial year 2021-22.

SECRETARIAL AUDIT



Pursuant to the provisions of Section 204 of the Companies Act, 2013 and Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, your Company has appointed PI & Associates, Practicing Company Secretaries to undertake the Secretarial Audit of the Company for the financial year 2021-22. The Report of the Secretarial Audit Report is enclosed as **Annexure C**.

INTERNAL CONTROLS



Your Company has an adequate system of Internal Control in place.

Internal Financial Controls are part and parcel of process & system procedures. It is being monitored by the Company on regular basis.

RISK MANAGEMENT



With regard to Risk Management of the Company, your Company has formulated a Risk Management Committee in accordance with the IRDAI Corporate Governance Guidelines. Also, the Risk Policy of the Company has been approved and reviewed by the Board. Policy elaborates the detailed description of type of risk and its monitoring plan. As a process, key risk to which Company is exposed during the quarter is placed and discussed in the Risk Committee Meeting and the same is updated to the Board.

AWARDS, CERTIFICATES AND RECOGNITION

During the financial year 2021-22, your Company has been conferred with the following awards:

- India's Best Health Insurance Product at Insurance Alertss Awards 2021
- India's Best Health Insurance Agents at Insurance Alertss Awards 2021

Further, your Company has an overall ranking of "8th" in the Health Insurance Segment as on March 31, 2022. Your Company has adopted Business Continuity Management Systems based on ISO 22301:2019 which specifies the requirements for a **Business Continuity Management System (BCMS)** in order to demonstrate its ability to protect against, reduce the likelihood of occurrence, prepare for, respond to, and recover from disruptive incidents when they arise and provide uninterrupted products and services that meet customer and applicable statutory and regulatory requirements,

The scope of your Company for BCMS includes the following offices:

- Corporate Office located at 3rd Floor, Vipul Tech Square, Golf Course Rd., Sector 43, Gurgaon - 122009,
- Call Center located at Call Centre & Web assistance Operational Hubs 1st & 2nd Floor Plot no F1, Sector - 6, Noida-201301
- Correspondence Office located at Unit no 604 - 607, 6th Floor, Tower C, Unitech Cyber Park, Sector 39, Gurgaon - 122001

With this your Company was able to understand and prioritize the threats to the business with the international standard for business continuity. ISO 22301: 2019 specifies the requirements for a management system to protect against, reduce the likelihood of and ensure your business recovers from disruptive incidents.

DIRECTOR'S RESPONSIBILITY STATEMENT

In accordance with the requirements of Section 134(5) of the Companies Act, 2013 the Board of Directors hereby state and confirm that:

- a) In the preparation of the annual accounts for the year ending March 31, 2022, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the company for that period;

- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis; and
- e) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

In addition, the Company has complied with the revised Secretarial Standards as issued by ICSI.

ANNUAL RETURN

A copy of annual return is placed on the website of the Company and the same can be accessed from the following web link:

https://cms.careinsurance.com/cms/public/uploads/uploads/other_disclosure/AnnualReturn_1653455070.pdf


Note: The link will be available within 60 days from the date of the Annual General Meeting of the Company.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS



There has been no order passed by any Regulator, Court or Tribunal against the Company which can impact its going concern status and Company's operation in future.

CONSERVATION OF ENERGY AND TECHNOLOGY ABSORPTION



Your Company is not engaged in manufacturing activities and, therefore, the particulars as required under the Companies Act, 2013 regarding Conservation of Energy, Research and Development and Technology Absorption are not applicable.

FOREIGN EXCHANGE EARNINGS AND OUTGO



The Foreign Exchange earned in terms of actual inflows during the year 2021-22 is Rs. 44.74 Crores and the Foreign Exchange outgo in terms of actual outflows during the year 2021-22 is Rs. 42.81 Crores.

FORMAL ANNUAL EVALUATION



The Board of Directors in its meeting held on January 23, 2015 and further in its meeting held on November 03, 2020 had adopted the Board Evaluation policy in accordance with Sections 134, 178 and Schedule IV of the Companies Act, 2013 ("Act") read with applicable Regulations under the Act. The Salient feature of the Policy is as follows:

The performance evaluation framework consists of three parts as per below:

- Performance Evaluation of Committees
- Performance Evaluation of the Board as a whole
- Performance Evaluation of Individual Directors

Performance Evaluation of the Committees and Board as a whole

- The Board had carried out annual evaluation of its Committees and Board through self-evaluation Form which was circulated by the Board Designee prior to the Committee Meeting(s) and Board Meeting.
- The evaluation form consisted of certain criteria on the basis of which individual Directors rated the respective Committee(s) and the Board.

- The Board Designee then tabulated the results and shared the summary report with the Committee(s) members and the Board. The summary report included the score against each of the evaluation criteria & verbatim comments without any names.
- The Committee(s) and the Board discussed the individual feedback, broad & common areas that were working well and those that needed attention.
- The Board Designee also presented the summary report to the Board of all the Committee(s) and the Board in the Annual Board Meeting.

Performance Evaluation of Individual Directors

- The Board and NRC carried out performance evaluation of individual directors through peer evaluation of each Board member during the Annual Board Meeting itself. The Chairman of the Board initiated the evaluation process where each Board member evaluated each of their colleagues on the Board.
- During the Annual Board Meeting, each Board member was given an evaluation form to rate each of their colleagues on the Board. The Board members do not have to disclose his/her name on the evaluation form.
- Once all the evaluation forms were placed in designated envelopes, each Board member had the opportunity to go through their own peer evaluation scores during the meeting itself.

The Board members and Committee members evaluated the Board and the Committee respectively and also evaluated the peer directors in the meeting of Board and its Committees held on April 26, 2022.

PARTICULARS OF EMPLOYEES



The information required pursuant to Section 197 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees of the Company has been provided in **Annexure D**. Any Shareholder interested in obtaining a copy of the said Annexure may write to the Company Secretary.

Further with regard to remuneration of KMPs in accordance to the IRDAI Corporate Governance Guidelines, the remuneration was discussed by the Nomination & Remuneration Committee. The consolidated remuneration paid to KMPs defined as per IRDAI Corporate Governance Guidelines is Rs.15,83,88,202/-

COMPLIANCE WITH SECRETARIAL STANDARDS

The Institute of Company Secretaries of India, a statutory body, has issued Secretarial Standards (SS) on various aspects of corporate law and practices. The Company has complied with the SS -1 on Board Meetings and SS - 2 on General Meetings.

APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

No application was made neither any proceeding is pending under the Insolvency and Bankruptcy Code, 2016 for the FY 2021-2022

CERTIFICATION UNDER IRDAI CORPORATE GOVERNANCE GUIDELINES

As per the revised IRDAI Corporate Governance Guidelines issued by IRDAI on May 18, 2016, Annual report of insurers will have a separate certification from the compliance officer in the prescribed format.

Accordingly, a Certificate for compliance of the Corporate Governance Guidelines is enclosed as **Annexure E**.

ACKNOWLEDGEMENT

The Board wishes to place on record its sincere appreciation for the continued assistance, support and co-operation extended to your Company by the Shareholders, Insurance Regulatory and Development Authority of India, the Auditors of your Company, Banks, other Government Authorities, Distribution Partners and Employees during the year under review and look forward to their continued support in the future.

**By order of the Board of Directors
For Care Health Insurance Limited**

**Dr. Rashmi Saluja
Chairperson**

**Place: Gurugram
Dated: April 26, 2022**

[Annexure -II]

Format for the Annual Report on CSR Activities to be Included in the Board's Report For Financial Year Commencing on or After 1st Day of April, 2021

1. Brief outline on CSR Policy of the Company.

The Corporate Social Responsibility Policy of the Company has been approved by the Board vide circular resolution dated February 05, 2020 in accordance to the Corporate Governance Guidelines dated May 18, 2016 issued by the Insurance Regulatory and Development Authority of India (IRDAI) along with Section 135 of the Companies Act, 2013 and Companies (Corporate Social Responsibility) Rules, 2014.

In light of the aforesaid guidelines and in compliance with Section 135 of the Companies Act, 2013, the Company has formed a CSR Committee. The Company's CSR activities as defined under the said Policy focus activities under Schedule VII such as promoting consumer awareness and protection, eradicating hunger, poverty and malnutrition, promoting healthcare including preventive healthcare, ensuring environment sustainability and ecological balance, supporting skill development and generation of employment, promoting education across the continuum- primary, secondary and tertiary especially among children, women, elderly and the differently-abled.

During the Financial year 2021-22, the Company has spent expenditure towards renovation, upgradation and maintenance of primary school in Nandgaon, Dist. Mathura, Uttar Pradesh of about Rs. 0.49 crore including GST and had modified its existing plan to spend the remaining amount of Rs. 0.83 crore including GST on an on-going basis towards the renovation, upgradation and maintenance of Prem Mahavidyalaya, Mathura, Uttar Pradesh in accordance to the CSR policy.

2. Composition of CSR Committee:

Pursuant to Guidelines for Corporate Governance for insurers in India dated May 18, 2016 and any other amendment(s) thereof, Section 135 of the Companies Act, 2013, read with Rule 5 of the Companies (Corporate Social Responsibility) Rules, 2014 as applicable and any other applicable provisions of the Companies Act, 2013 read with Rules thereunder and amendments thereof (including any statutory modifications or re-enactment thereof, for the time being in force), the Board of Directors of the Company accorded its approval to constitute a CSR Committee of the Company with the following members:

Sl. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Dr. Rashmi Saluja	Non-Executive Chairperson	1	1
2	Mr. Malay Kumar Sinha	Non-Executive Independent Director	1	1
3	Mr. Hamid Ahmed*	Non-Executive Independent Director	1	0
4	Lt. Gen. (Ret.) S.S. Mehta	Non-Executive Independent Director	1	1
5	Mr. Kartikeya Dhruv Kaji	Non-Executive Director	1	1
6	Mr. Anuj Gulati	Managing Director & CEO	1	1
7	Mr. Siddharth Dinesh Mehta**	Non-Executive Director	1	1

*Mr. Hamid Ahmed was appointed as a member w.e.f November 16, 2021.

** Mr. Siddhartha Dinesh Mehta resigned from the Board of Directors and various Committees w.e.f. December 31, 2021.

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:

https://cms.careinsurance.com/cms/public/uploads/uploads/other_disclosure/CSR-POLICY_1586761680.pdf

4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report).- Not applicable.

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

Sl. No.	Financial Year	Amount available for set-off from preceding financial years (in Rs)	Amount required to be set-off for the financial year, if any (in Rs)
1	2021-22	Rs. 6000/-	Rs. 6000/-
2			
3			
	Total	Rs. 6000/-	Rs. 6000/-

6. Average net profit of the company as per section 135(5).

S.no	Financial Year	Net Profit (Before Tax) (in rupees Cr.)
1	2018-19	56.92
2	2019-20	65.89
3	2020-21	75.48
Total		198.29
Avg. Net Profit (before tax) for Preceding three Financial Years		66.10
CSR Expenditure required (2% of Average Profit)		1.32

7. (a) Two percent of average net profit of the company as per section 135(5)- Rs. 1.32 crore (including GST)

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years.-NIL

(c) Amount required to be set off for the financial year, if any- Rs. 6000/-

(d) Total CSR obligation for the financial year (7a+7b-7c)- Rs. 1.3194 crore (including GST)

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in Rs.)	Amount Unspent (in Rs.)- Rs.				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
49,60,695 (including GST)	Not Available	NA	NA	NA

(b) Details of CSR amount spent against ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------

Sl. No.	Name of the Project.	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Project duration.	Amount allocated for the project (in Rs.).	Amount spent in the current financial year (in Rs.).	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.).	Mode of Implementation - Direct (Yes/No).	Mode of Implementation - Through Implementing Agency	
				State.	District.						Name	CSR Registration number
1.	Renovation, upgradation and maintenance of primary school in Nandgaon, Dist. Mathura, Uttar Pradesh	Promoting education, including special education and employment enhancement projects especially among children, women, elderly and the differently abled and livelihood enhancement projects.	No	Uttar Pradesh/ Mathura	Ongoing Basis	Upto 1.32 Crore	48,83,995	NA	Yes	-	-	
2.	Renovation, upgradation and maintenance of Prem Mahavidyalaya, Mathura, Uttar Pradesh	Promoting education, including special education and employment enhancement projects.	No	Uttar Pradesh/ Mathura	13 Months	0.83 Crore	76,700	82,33,305	Yes	-	-	

Pradesh	g vocation skills especiall y among children, women, elderly and the differentl y abled and livelihoo d enhance ment projects.									
Total					1.32 Crore	49,606 ,95	82,33,3 05			

(c) Details of CSR amount spent against other than ongoing projects for the financial year: NIL

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	
Sl. No.	Name of the Project	Item from the list of activities in schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Amount spent for the project (in Rs.).	Mode of implementation - Direct (Yes/No).	Mode of implementation - Through implementing agency.	
				State.	District.			Name.	CSR registration number.
1.									
	Total								

(d) Amount spent in Administrative Overheads:

(e) Amount spent on Impact Assessment, if applicable- NA

(f) Total amount spent for the Financial Year (8b+8c+8d+8e): 49,606,95

(g) Excess amount for set off, if any: Rs. 6000

Sl. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the company as per section 135(5)	Rs. 1.32 Crore
(ii)	Total amount spent for the Financial Year
(iii)	Excess amount spent for the financial year [(ii)-(i)]	NIL

(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Rs. 0.06 Lakhs
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	Rs. 0.06 Lakhs

9. (a) Details of Unspent CSR amount for the preceding three financial years: NA

Sl. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Amount spent in the reporting Financial Year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in Rs.)
				Name of the Fund	Amount (in Rs).	Date of transfer.	
1.							
2.							
3.							
	Total						

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):-NA

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No.	Project ID.	Name of the Project.	Financial Year in which the project was commenced.	Project duration.	Total amount allocated for the project (in Rs.).	Amount spent on the project in the reporting Financial Year (in Rs.).	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project - Completed /Ongoing.
1								
2								
3								
	Total							

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year

(asset-wise details).

(a) Date of creation or acquisition of the capital asset(s).

- (b) Amount of CSR spent for creation or acquisition of capital asset.
- (c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.
- (d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset).

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). NA

(Managing Director & CEO)	(Chairperson CSR Committee)	[Person specified under clause (d) of sub-section (1) of section 380 of the Act] (Wherever applicable)
---------------------------	-----------------------------	--

CARE HEALTH INSURANCE LIMITED

(Formerly known as Religare Health Insurance Company Limited)



HEALTH INSURANCE

Policy on Director's Appointment
(CHIL/POL/125/011)

Prepared by:
Head - Payroll & HR
Operations

Reviewed by:
Head – Human Resources

Proposed Approved by:
Board of Directors

COPYRIGHT (c)

No part of this document may be reproduced in any form by print, photocopy, microfilm or any other means wholly or partially, or disclosed to any person outside CHIL without a written permission



Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
(CHIL/POL/125/011)

Initial Issue Date:
28.07.2014

Revision:
04

Revision Date:
01.11.2021

Page 2 of 4

Title: **Policy on Director's Appointment**

1. PREAMBLE

The Board of Directors (the "Board") of Care Health Insurance Limited (the "Company" or "CHIL"), has adopted the following policy and procedures with regard to appointment of Directors as defined below. The Nomination and Remuneration Committee will review and may amend this policy from time to time.

This policy will be applicable to the Company. This policy is to regulate the appointment of Directors (including the Independent Directors) based on the laws and regulations applicable on the Company. The remuneration for Whole-Time Directors/ CEO / Managing Director / Non-Executive Directors is covered under separate Policy i.e. Policy on Remuneration of Directors.

2. PURPOSE

This policy is framed as per requirement of Sections 134, 178, Schedule IV of the Companies Act, 2013 ("Act") read with applicable Regulations under the Act, and Regulations/ Guidelines/ Circulars including but not limited to Corporate Governance Guidelines issued by Insurance Regulatory and Development Authority and subsequent amendments thereof and intended to have a Board with diverse background and experience in areas that are relevant for the Company, to ensure the proper appointment of the Directors of the Company and at the same time to attract and retain the best suitable talent on the Board of the Company.

3. DEFINITIONS

"Nomination and Remuneration Committee (NRC)" means Committee of Board of Directors of the Company constituted under provisions of Companies Act, 2013.

"Board" means Board of Directors of the Company

"Policy" means Director's Appointment Policy.

"CEO" means the Chief Executive Officer of the Company.

"Whole-Time Director" as defined under the Companies act, 2013

"Non-Executive Director" means a person who is not employee of the Company

"Managing Director" as defined under the Companies Act, 2013

"Company" means Care Health Insurance Limited

4. POLICY

- 4.1. The Nomination & Remuneration Committee (NRC) determines the criteria of appointment to the Board and is vested with the authority to identify candidates for appointment to the Board of Directors. The NRC, along with the Board, on continuous basis will review appropriate skills, characteristics and experience required of the Board as a whole and its individual members. The objective is to have a Board with diverse background and experience in areas that are relevant for the company.



Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
(CHIL/POL/125/011)

Initial Issue Date:
28.07.2014

Revision:
04

Revision Date:
01.11.2021

Page 3 of 4

Title: **Policy on Director's Appointment**

- 4.2. In evaluating the suitability of individual Board member, the NRC will take into account multiple factors, including general understanding of the business, education, professional background, personal achievements, etc. Few important criteria against which each prospective candidate will also be evaluated are personal and professional ethics, integrity and values. He / She should be willing to devote sufficient time and effort in carrying out their duties and responsibilities effectively & must have the aptitude to critically evaluate management's working as part of a team.
- 4.3. The NRC will evaluate each prospective candidate with the objective of having a group that best enables the success of the company's business.
- 4.4. The NRC may make independent / discreet references, where necessary well in time to verify the accuracy of the information furnished by the applicant.
- 4.5. The NRC shall scrutinize the declarations of intending applicants before the appointment / reappointment / election of Directors by the shareholders at the General Meetings.
- 4.6. Based on recommendation of the NRC, the Board will evaluate the candidate(s) and decide on the selection of the appropriate member. The Board through the CEO / NRC will make an invitation to the new member to join the Board as a Director. On acceptance of the same, the new Director will be appointed by the Board.
- 4.7. The NRC may review the Deed of Covenant required to be entered by Directors at the time of appointment.
- 4.8. The form and amount of director remuneration will be recommended by the NRC to the Board for approval within the maximum amount permissible under the law. Employee directors will not be paid for Board membership in addition to their regular employee compensation. The rest of terms and conditions with regard to remuneration shall be governed by separate policy i.e. Policy on Remuneration of Directors.
- 4.9. The NRC shall also ensure that the proposed appointments / reappointments of Directors are in conformity with the Board approved policy on retirement / superannuation.

5. EFFECTIVE DATE OF POLICY

This Policy will come into effect from the date of approval of the same by the Board of Directors of Company.



HEALTH INSURANCE

Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
(CHIL/POL/125/011)Initial Issue Date:
28.07.2014Revision:
04Revision Date:
01.11.2021

Page 4 of 4

Title: **Policy on Director's Appointment****6. AMENDMENT HISTORY:**

Version No.	Description	Date	Prepared By	Reviewed By	Approved By
1.1	Director's Appointment and Remuneration Policy	28 th July 14	Varidhi Gosain	Gaurav Bakshi	Board of Directors
1.2	Reinstated	26 th July16	Amit Mishra	Sanjeev Meghani	Board of Directors
1.3	a. Director's Appointment & Remuneration Policy has been segregated into separate policies. b. Content Change - Clauses around scrutiny of applicants etc.	24 th Oct16	Abhimanyu Sodhi	Sanjeev Meghani	Board of Directors
1.4	Reinstated	07 th Nov17	Abhimanyu Sodhi	Sanjeev Meghani	Board of Directors
1.5	Reinstated	02 th Nov18	Amit Gupta	Sanjeev Meghani	Board of Directors
2	Reinstated. Also ISO format has been revised	05 th Feb 20	Amit Gupta	Sanjeev Meghani	Board of Directors
3	Formatting as per re-branding	03 rd Nov 20	Amit Gupta	Sanjeev Meghani	Board of Directors
4	Review	01 st Nov 21	Amit Gupta	Sanjeev Meghani	Board of Directors

CARE HEALTH INSURANCE LIMITED
(Formerly known as Religare Health Insurance Company Limited)



Policy on Remuneration of Directors
(CHIL/POL/125/009)

Prepared by:
Head - Payroll & HR
Operations
Signature:

Reviewed by:
Head – Human
Resources
Signature:

Approved by:
Board of Directors
Signature:

COPYRIGHT (c)

No part of this document may be reproduced in any form by print, photocopy, microfilm or any other means wholly or partially, or disclosed to any person outside CHIL without a written permission



Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
CHIL/POL/125/009

Initial Issue Date:
24.10.2016

Revision:
04

Revision Date:
01.11.2021

Page 1 of 5

Title: **Policy on Remuneration of Directors**

1.0 INTRODUCTION

The Board of Directors (the “Board”) of Care Health Insurance Limited (the “Company” or “CHIL”), has adopted the following policy and procedures with regard to remuneration of CEO (Chief Executive Officer) / MD (Managing Director) / WTD (Whole Time Director) / Non-Executive Director as defined below in line with guidelines provided by IRDA’s circular no. IRDA/F&A/GDL/LSTD/155/08/2016 dated August 05, 2016.

2.0 OBJECTIVES

To lay down the framework that governs determination of remuneration of CEO (Chief Executive Officer) / MD (Managing Director) / WTD (Whole Time Director) / Non-Executive Director. The policy lays down the indicative structure of remuneration (in terms of various components of compensation) and also links it to the key risks associated with business.

3.0 DEFINITIONS

“**Act**” includes the Companies Act, 2013, rules thereof and any such guidelines, circulars or rules issued by IRDAI with regard to remuneration of Directors from time to time.

“**Nomination and Remuneration Committee (NRC)**” means Committee of Board of Directors of the Company constituted under provisions of Companies Act, 2013.

“**Board**” means Board of Directors of the Company

“**Policy**” means Remuneration Policy for CEO (Chief Executive Officer) / MD (Managing Director) / WTD (Whole Time Director) and Non-Executive Directors.

“**Company**” means Care Health Insurance Limited

“**CEO / MD / WTD / Non-Exe Director**” means Chief Executive Officer / Managing Director / Whole Time Director / Non-Executive Director of the Company as defined under the Companies act, 2013 or corporate governance guidelines by IRDAI.

“**Total Pay**” means fixed pay plus variable pay

“**Authority**” is Insurance Regulatory Development Authority of India

4.0 POLICY GUIDELINES FOR CEO / MD / WTD

4.1. GENERAL

- The remuneration / compensation / commission etc. to CEO / MD / WTD will be determined by the Nomination and Remuneration Committee and recommended to the Board for approval
- No revision in remuneration shall be permitted till the expiry of one year from the date of earlier approval by the Authority
- In case the annual remuneration exceeds Rs. 1.5 crore (including all perquisites plus bonuses etc.), such excess shall be borne by the Shareholder's account
- No remuneration shall be paid to CEO / MD / WTD by any of the promoter / investor or by any group companies of the promoters' / investors' companies
- Other than accrued benefits (gratuity, pension etc.) severance pay shall not include any other payments without prior approval of the Board. Severance pay shall not include notice period pay.

4.2. REMUNERATION COMPOSITION & GUIDELINES

- I. There should be a proper balance between fixed pay and variable pay.
- II. **Fixed Pay:** Fixed portion of remuneration shall be reasonable taking into account all relevant factors.
- III. **Variable Pay:** This may include any payment other than fixed pay
 - The variable pay could be in cash, stock linked instruments or mix of both. However, Employees Stock Option Plan (ESOP) is excluded from components of variable pay.
 - In case of deterioration in financial performance of the Company and other parameters specified in clause 4.4 of this policy, there may be contraction in the total amount of variable remuneration paid as may be decided by the NRC.
 - If at any point of time, the NRC is of the opinion that the variable pay forms a substantial portion of the total pay, the NRC may recommend pro-rated deferment of the portion of the variable pay that exceeds the "substantial" amount of the total pay over a period of not less than 3 years. Variable pay under deferral arrangement should vest no faster than on pro rata basis.
 - The NRC may decide on the "substantial" amount as mentioned above, from time to time based on business performance.
 - There should be proper balance between the cash and stock / share components (other than ESOP) in the variable pay in case the variable remuneration contains stock or equity share linked instruments (other than ESOP).

Title: Policy on Remuneration of Directors

IV. ESOP: For the purpose of this policy and based on IRDAI guidelines referenced in the above mentioned circular no., ESOP will not be considered as part of total remuneration. For CEO, ESOP shall continue to be separately governed by CEO Stock Option Scheme – 2014.

In case the shares of the insurance company are offered as ESOPs to CEO / MD / WTD, then:

- If CEO / MD / WTD is one of the promoters / investors of directly related to the promoters, then the same will be governed by provisions of SEBI (Issue of Sweat Equity) Regulations, 2002 as amended from time to time except those relating to pricing of shares. The manner of pricing of shares shall be disclosed upfront to the Authority.

4.3. CLAWBACK

- In case of deferral remuneration, in the event of any negative trend in the parameters specified in Clause 4.4. of this policy during the vesting period, any unvested / unpaid portions of the deferred payment are to be clawed back. However, while exercising this provision, due consideration may be given to the actual / realized performance of the Company as may be decided by the NRC.
- The NRC may at any appropriate time, may put in place a mechanism to link clawback to such parameters as mentioned in point no. 4.4 of this policy.

4.4. RECOMMENDATION FOR REMUNERATION REVISION

While recommending the revision in remuneration to the Board for approval, the Nomination and Remuneration Committee shall consider Company's standing in light of risks associated with the following parameters:

- Persistency
- Solvency
- Grievance Redressal
- Expenses of Management
- Claim Ratio
- Claim repudiations
- Overall Compliance status
- Net-Worth Position of the Company
- Asset Under Management (AUM)

5.0 POLICY GUIDELINES FOR NON- EXECUTIVE DIRECTORS

5.1. The NRC may recommend to the Board to pay remuneration in the form of profit related commission to the Non-Executive Directors, subject to the Company making profits. Such remuneration, however, shall not exceed Rs. 10 Lakhs per annum for each such Director.



Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
CHIL/POL/125/009

Initial Issue Date:
24.10.2016

Revision:
04

Revision Date:
01.11.2021

Page 4 of 5

Title: **Policy on Remuneration of Directors**

5.2. Sitting Fees and reimbursement of expenses: In addition to the Director's remuneration mentioned in clause 5.1, the NRC may recommend to the Board to pay sitting fees to the Non-Executive Directors and reimburse their expenses for participation in the Board and other meetings, subject to compliance with the provisions of the Companies Act, 2013.

6.0 POLICY GUIDELINES FOR INDEPENDENT DIRECTORS

- 6.1.** The NRC may recommend to the Board to pay Independent Directors remuneration/commission as per applicable provisions of laws for the time being in force and within the overall limits as defined under the Act.
- 6.2.** The NRC may recommend to the Board to pay Independent Directors sitting fees for attending the meetings of the Board or Committees, thereof either personally or through Video Conference or other audio visual means or for any other purpose whatsoever as may be decided by the Board of Directors.
- 6.3.** The aforesaid sitting fees payable shall be subject to applicable tax deduction at source. In addition to the above, Independent Directors will be entitled to reimbursement of all expenses for participation in the Board and other meetings.
- 6.4.** The Independent Directors shall not be entitled to any ESOP as defined under the Act.

7.0 POLICY REVIEW

The Nomination & Remuneration Committee will review this policy and recommend necessary changes to the Board.

8.0 AMENDMENTS

The Board of Directors on its own and / or as per the recommendations of Remuneration Committee can amend this policy, as deemed fit from time to time.

9.0 Effective Date of the Policy

This Policy will come into effect from the date of approval of the same by the Board of Directors of the Company



Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
CHIL/POL/125/009

Initial Issue Date:
24.10.2016

Revision:
04

Revision Date:
01.11.2021

Page 5 of 5

Title: **Policy on Remuneration of Directors**

10.0 AMENDMENT HISTORY:

Version No.	Description	Date	Prepared By	Reviewed By	Approved By
1	Policy on Remuneration of Directors	24 th Oct16	Abhimanyu Sodhi	Sanjeev Meghani	Board of Directors
1.2	Reinstated	07 th Nov17	Abhimanyu Sodhi	Sanjeev Meghani	Board of Directors
1.3	Reinstated	02 th Nov18	Amit Gupta	Sanjeev Meghani	Board of Directors
2	Reinstated. Also ISO format has been revised.	05 th Feb 20	Amit Gupta	Sanjeev Meghani	Board of Directors
3	Organization Name Change	03 rd Nov 20	Amit Gupta	Sanjeev Meghani	Board of Directors
4	Review	01 st Nov 21	Amit Gupta	Sanjeev Meghani	Board of Directors

CARE HEALTH INSURANCE LIMITED

(Formerly known as Religare Health Insurance Company Limited)



HEALTH INSURANCE

**KMP's Appointment and Remuneration Policy
(CHIL/POL/125/008)**

Prepared by:
Head - Payroll & HR
Operations

Reviewed by:
Head – Human Resources

Proposed Approved by:
Board of Directors

COPYRIGHT (c)

No part of this document may be reproduced in any form by print, photocopy, microfilm or any other means wholly or partially, or disclosed to any person outside CHIL without a written permission 55



HEALTH INSURANCE

Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)

Doc. No.:
(CHIL/POL/125/008)Initial Issue Date:
28.07.2014Revision:
04Revision Date:
01.11.2021

Page 2 of 4

Title: **KMP's Appointment and Remuneration Policy**

1. PREAMBLE

The Board of Directors (the "Board") of Care Health Insurance Limited (the "Company" or "CHIL"), has adopted the following policy and procedures with regard to appointment and remuneration of Key Managerial Personnel's ("KMP") as defined below. The Nomination and Remuneration Committee will review and may amend this policy from time to time.

This policy will be applicable to the Company. This policy is to regulate the appointment and remuneration of KMP's based on the laws and regulations applicable on the Company.

2. PURPOSE

This policy is framed as per requirement of Sections 178 and 203 of the Companies Act, 2013 ("Act") read with applicable Regulations under the Act, Corporate Governance Guidelines issued by Insurance Regulatory and Development Authority of India ("IRDAI") and subsequent amendments thereof and intended to ensure the proper appointment and fairness in the remuneration process of the KMP's of the Company and at the same to attract and retain the best suitable talent for the Company.

3. DEFINITIONS

"Nomination and Remuneration Committee" means Committee of Board of Directors of the Company constituted under provisions of Companies Act, 2013 and Corporate Governance Guidelines issued by IRDAI

"Board" means Board of Directors of the Company

"HR Head" means person heading the Human Resource Department of the Company

"Key Managerial Personnel" means key managerial personnel as defined under the Companies Act, 2013 and includes

S. No.	Key Managerial Position	Current Incumbent
1	Chief Executive Officer	Anuj Gulati
2	Chief Financial Officer	Pankaj Gupta
3	Company Secretary	Pratik Kapoor
4	Chief Marketing Officer	Ajay Shah
5	Head - Institutional Business	Chandrakant Mishra
6	Chief Risk Officer	Manish Dodeja
7	Appointed Actuary	Irvinder Singh Kohli
8	Chief Compliance Officer	Anoop Singh
9	Head - Human Resources	Sanjeev Meghani
10	Chief Investment Officer	Nitin Katyal
11	Chief of Internal Audit	Bhawana Jain

“Policy” means KMP's Appointment and Remuneration Policy

“Company” means Care Health Insurance Limited

“CEO” means the Chief Executive Officer of the Company

“Managing Director / Whole-Time Director” as defined under the Companies Act, 2013

4. POLICY

- 4.1. The authority to identify right candidates for appointment of KMP's is vested with the CEO. The CEO along with HR Head will identify candidates internally or externally and will propose to Nomination and Remuneration Committee (“NRC”). The NRC will put forth its recommendation for the appointment and remuneration of KMP before the board for its approval. The remuneration will be proposed in consistent with the strategy of the company and in line with the comparable market & internal remuneration benchmarks.
- 4.2. The NRC will scrutinize the declarations of intending applicants before the appointment of KMPs in the Form KMP -1, as prescribed under the Corporate Governance guidelines issued by IRDAI or any another form and manner as may be prescribed under any act or guidelines, from time to time.
- 4.3. The NRC while scrutinizing the declaration of applicants, may make independent/discreet references, wherever necessary, well in time to verify the accuracy of the information furnished by the applicant and then recommend Appointment of KMPs to the Board for further action.
- 4.4. The NRC while considering the KMPs appointment will also ensure that KMPs shall not hold simultaneously another position as KMP in the Company.
- 4.5. The NRC needs to ensure that the position of any KMPs should not be vacant for more than 180 days.
- 4.6. The NRC will also recommend the termination of KMPs to the Board for further action.
- 4.7. In case of CEO's/Managing Director/Whole-time Director appointment, NRC will initiate the process of identifying the new Chief Executive Officer. After identification of the candidate, NRC will propose the candidature to Board for its approval for appointment. Remuneration of CEO/Managing Director/Whole-time Director shall be governed under another Policy named as Policy on Remuneration of Directors.

5. EFFECTIVE DATE OF POLICY

This Policy will come into effect from the date of approval of the same by the Board of Directors of Company.



HEALTH INSURANCE

Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)Doc. No.:
(CHIL/POL/125/008)Initial Issue Date:
28.07.2014Revision:
04Revision Date:
01.11.2021

Page 4 of 4

Title: **KMP's Appointment and Remuneration Policy****6. AMENDMENT HISTORY:**

Version No.	Description	Date	Prepared By	Reviewed By	Approved By
1.1	KMP's Appointment and Remuneration Policy	28 th July 14	Varidhi Gosain	Gaurav Bakshi	Board of Directors
1.2	Reinstated	26 th July16	Amit Mishra	Sanjeev Meghani	Board of Directors
1.3	a. Categories have been added to the definition of KMP as per IRDA guidelines b. Content Change – Process for approval of KMP, Closure timeline of KMP vacancy etc.	24 th Oct16	Abhimanyu Sodhi	Sanjeev Meghani	Board of Directors
1.4	Change in KMP list – Irvinder name has been added against Appointed Actuary	07 th Nov 17	Abhimanyu Sodhi	Sanjeev Meghani	Board of Directors
1.5	Reinstated	02 th Nov 18	Amit Gupta	Sanjeev Meghani	Board of Directors
2	Reinstated. Also ISO format has been revised.	05 th Feb 20	Amit Gupta	Sanjeev Meghani	Board of Directors
3	Formatting as per re-branding	03 rd Nov 2020	Amit Gupta	Sanjeev Meghani	Board of Directors
4	Review	01 st Nov 2021	Amit Gupta	Sanjeev Meghani	Board of Directors

FORM NO. MR - 3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2022

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule no.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Care Health Insurance Limited
(Formerly known as Religare Health Insurance Company Limited)
(U66000DL2007PLC161503)

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Care Health Insurance Limited (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon. This Company is governed mainly under the provisions of the Insurance Act, 1938 and the Insurance Regulatory and Development Authority Act, 1999 ("Insurance Laws") and under the Companies Act, 2013 and rules framed thereunder where there is no inconsistency with the Insurance Laws.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company, the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent and as applicable to the Company, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records made available to us and maintained by the Company for the financial year ended on March 31, 2022 as mentioned in *Annexure-A and Annexure-B*, according to the provisions of:

Page 1 of 6

CORPORATE OFFICE

D-38, South Extension Part - I, New Delhi - 110049 India | +91 11 40622200 | info@piassociates.co.in

- (i) The Companies Act, 2013 ("the Act") and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ("SCRA") and the rules made thereunder; (*Not applicable to the Company during the audit period*)
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (*Not applicable to the Company during the audit period*)
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"): -
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (*Not applicable*)
 - d. The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (*to the extent applicable to the Company*)
 - e. The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; (*Not applicable*)
 - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 20021; (*Not applicable*)
 - h. The Securities and Exchange Board of India (Buy - back of Securities) Regulations, 2018; (*Not applicable*)
 - i. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (*Not applicable*)
- (vi) And the Company being in the business of Insurance other than Life Insurance, the Special Act as applicable to it is the Insurance Act, 1938 and extant Rules & Regulation framed under Insurance Regulatory and Development Authority Act, 1999 ("IRDA").

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to board and general meetings; and
- (ii) The Listing Agreements entered into by the Company with the Stock Exchange(s), if applicable.
(Not applicable)

We further report that:

- I. The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Companies Act, 2013 and IRDAI Regulations incl. CG Guidelines.
- II. Adequate notice was given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance for meetings other than those held at shorter notice, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- III. Majority decisions were carried through and there were no instances where any director expressing any dissenting views.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period the Company had following events which had bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.:

- I. That the Company allotted 3,29,24,677 equity shares amounting to Rs. 89,80,40,097/- (in aggregate) comprising of 1,08,39,024 equity shares of face value of Rs. 10 each, 27,00,000 equity shares of face value of Rs 10 each @ premium of Rs. 11.85 per share, 10,80,317 equity shares of face value of Rs. 10 each @ premium of Rs. 24.31 per share and 1,83,05,336 equity shares of face value of Rs. 10 each @ premium of Rs. 27.89 per share, to Mr. Anuj Gulati, Managing Director & CEO of the Company pursuant to ESOP options exercised by CEO under Religare Health Insurance CEO Stock Option Scheme 2014.

- II. That pursuant to the application made by the Company seeking exemption under Regulation 11(ii) of IRDAI (Expenses of Management of Insurers transacting General or Health Insurance business) Regulations, 2018, the IRDAI, vide its letter dated April 5, 2022, has granted forbearance to the Company for Financial Year 2020-21 subject to compliance of certain conditions specified therein.
- III. That the Company increased the ESOP Pool to a total of 15% of the issued share capital (including options to be issued under Religare Health Insurance Stock Option Scheme 2014 ("RHICL ESOP Scheme, 2014") and Religare Health Insurance CEO Stock Option Scheme 2014 ("RHICL ESOP CEO Scheme, 2014") including any amendments (to be computed with reference to expanded capital on fully diluted basis) excluding outstanding warrants and conversions, from the current percentage of 12.5% of the issued share capital, by way of amendment to RHICL ESOP Scheme, 2014 and RHICL ESOP CEO Scheme, 2014 respectively and consequent alteration of Articles of Association of the Company.

For PI & Associates
Company Secretaries

Nitesh Latwal

Partner

ACS No.: 32109

C P No.: 16276

UDIN: A032109D000206492

Date: April 26, 2022

Place: New Delhi

The above report is to be read with our letter of even date which is annexed as "Annexure A and B" and forms an integral part of this report.

Page 4 of 6

CORPORATE OFFICE

D-38, South Extension Part - I, New Delhi - 110049 India | +91 11 40622200 | info@piassociates.co.in

Under Companies Act, 2013: -

1. Memorandum & Articles of Association of the Company.
2. Annual Report for the financial year ended March 31, 2021.
3. Minutes of the meetings of the Board of Directors, Audit Committee, Nomination & Remuneration Committee, Corporate Social Responsibility Committee, Stakeholders Relationship Committee, Allotment Committee and IPO Committee (along with Attendance Registers) held during the financial year under report.
4. Minutes of General Body Meetings held during the financial year ended March 31, 2022 under report.
5. Statutory Registers as per Companies Act 2013.
6. Agenda papers submitted to all the directors / members for the Board Meetings and Committee Meetings.
7. Declarations received from the Directors of the Company pursuant to the provisions of Section 149(6) & (7), Section 164 and Section 184 of the Companies Act, 2013.
8. E-Forms filed by the Company, from time-to-time, under applicable provisions of the Companies Act, 2013 and attachments thereof during the financial year under report.
9. Various Policies framed by the Company required under the Companies Act, 2013 viz. Nomination and Remuneration Policy, Corporate Social Responsibility Policy, Board Evaluation Policy etc.
10. Documents pertaining to Appointment, Resignation of Directors and KMP and approvals received from IRDAI.
11. Other relevant documents as required to be maintained and published on website by the Company.

Under Insurance Act, 1938 and Insurance Regulatory and Development Authority of India Act (IRDAI) 1999:-

1. Minutes of Investment Committee, Policyholders Protection Committee, Risk Management Committee required as per IRDAI Corporate Governance Guidelines along with Attendance Register, held during the financial year under report.
2. Deed of Covenants at the time of appointment.
3. Declaration and undertakings from Directors.
4. Compliance / Correspondence with IRDAI i.e. Monthly, Quarterly, Half yearly, Annually etc.
5. Documents pertaining to Appointment of Directors and KMP and approvals received from IRDAI.

“Annexure B”

Page 5 of 6

CORPORATE OFFICE

D-38, South Extension Part - I, New Delhi - 110049 India | +91 11 40622200 | info@piassociates.co.in

To,
The Members,
Care Health Insurance Limited

Our Secretarial Audit Report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our Responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Compliance Certificate about the compliance of laws, rules and regulation and happening of events etc.
5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards are the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For PI & Associates
Company Secretaries

Nitesh Latwal
Partner
ACS No.: 32109
C P No.: 16276
UDIN: A032109D000206492

Date: April 26, 2022

Place: New Delhi

Page 6 of 6



April 26, 2022

“Certification for compliance of the Corporate Governance Guidelines”

I, Pratik Kapoor, hereby certify that Care Health Insurance Limited has complied with the corporate governance guidelines for Insurance Companies as amended from time to time and nothing has been concealed or suppressed.

Pratik Kapoor
Company Secretary

INDEPENDENT AUDITOR'S REPORT

To The Members of Care Health Insurance Limited

Opinion

We have audited the accompanying financial statements of **Care Health Insurance Limited** (the Company), which comprise the Balance Sheet as at 31st March, 2022, and the Revenue Account, the Profit and Loss Account and the Receipts and Payments Account for the year ended 31st March, 2022 and notes to the financial statements, including a summary of Significant Accounting Policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements are prepared in accordance with the Insurance Act, 1938 as amended by the Insurance Laws (Amendment) Act, 2015, Insurance Regulatory and Development Authority Act, 1999, the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002, the Companies Act, 2013 ("the Act") including the applicable Accounting Standards specified under Section 133 of the Act read with the applicable rules, the current practices prevailing within the insurance industry in India and the orders / directions and circulars issued by the Insurance Regulatory and Development Authority of India ("IRDAI") in this regard, as amended, and in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India as applicable to insurance companies:

- a. in the case of the Balance Sheet, of the State of affairs of the Company as at 31st March, 2022;
- b. in the case of the Revenue Account, of its Surplus for the year ended on that date;
- c. in the case of the Profit and Loss Account, of its Profit for the year ended on that date; and
- d. in the case of the Receipts and Payments Account, of its Receipts and Payments for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matter

The estimate of Claims Incurred But Not Reported (IBNR) and Claims Incurred But Not Enough Reported (IBNER) have been certified by the Company's Appointed Actuary. The Appointed Actuary has certified to the Company that the assumptions used for such estimation are appropriate and are in accordance with the requirements of relevant regulation issued by IRDAI and Actuarial Practice Standards issued by Institute of Actuaries of India. We have relied upon on the Appointed Actuary's certificate in this regard for forming our opinion on the financial statements of the Company.

Our opinion is not modified in respect of the above matter.

Information Other than the Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Director's Report, and its annexures, but does not include the financial statements and our auditor's report thereon. The other information is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the other information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take appropriate actions, if required.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013, with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and receipts and payments of the Company, in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, the requirements of the Insurance Act, 1938 as amended by the Insurance Laws (Amendment) Act, 2015, Insurance Regulatory and Development Authority Act, 1999, the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002, and the orders / directions and circulars issued by the IRDAI in this regard, as amended, and in the manner so required.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate Internal Financial Controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide to those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other Legal and Regulatory Requirements

1. As the Company is not covered by the Companies (Auditor's Report) Order, 2016, ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, no report is given on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by the paragraph 2 of Schedule C to the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002, read with Section 143 (3) of the Companies Act, 2013, we report that:
 - a. We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit and found them to be satisfactory;
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c. As the Company's accounts are centralized and maintained at the corporate office, no returns for the purposes of our audit are prepared at the branches and other offices of the Company as required under Section 143(8) of the Act;
 - d. The Balance Sheet, the Revenue Account, the Profit & Loss Account and the Receipts and Payments Account dealt with by this report are in agreement with the books of account;
 - e. In our opinion, the Investments have been valued in accordance with the provisions of the Insurance Act 1938, as amended by the Insurance Laws (Amendment) Act, 2015, Insurance Regulatory and Development Authority Act, 1999, the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002 and orders / directions issued by IRDAI in this regard;
 - f. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with applicable rules, to the extent they are not inconsistent with the accounting principles prescribed in the Regulations and orders / directions issued by IRDAI in this regard;

- g. On the basis of the written representations received from the Directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a Director in terms of Section 164 (2) of the Companies Act, 2013.
- h. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure A**".
- i. Since the Company is an IRDAI regulated entity, therefore, the provisions of Section 197(16) of the Companies Act, 2013 w.r.t. managerial remuneration are not applicable. The remuneration (including bonus) paid / payable by the Company to the Managing Director and CEO is in accordance with the requirement of Section 34A of the Insurance Act, 1938.
- j. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 1 of Notes to accounts to the financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

v. No dividend was declared or paid during the year; hence, the said clause is not applicable.

3. We have issued a separate certificate in "**Annexure B**" of even date on the matters specified in paragraph 4 of Schedule C to the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002 issued by IRDAI.
4. Further, on the basis of our examination of books and records of the Company and according to the information and explanations given to us, we certify to the best of our knowledge and belief that:
 - a. We have reviewed the Management Report attached to the financial statements for the year ended 31st March, 2022 and have found no apparent mistake or material inconsistencies with the financial statements; and
 - b. Based on the information and explanations received during the normal course of our audit, management representations and compliance certificates submitted to the Board by the officers of the Company charged with the compliance and the same being noted by the Board, nothing has come to our attention which causes us to believe that the Company has not complied with the terms and conditions of registration stipulated by IRDAI.

For and on behalf of
T R Chadha & Co LLP
Chartered Accountants
Firm Regn. No. 006711N/N500028

For and on behalf of
S. P. Chopra & Co.
Chartered Accountants
Firm Regn. No.000346N

Hitesh Garg
Partner
M. No. 502955
UDIN: 22502955AHVYIY2775

Gautam Bhutani
Partner
M. No. 524485
UDIN: 22524485AHVYEP3231

Place: New Delhi
Date : 26.04.2022

Place: New Delhi
Date : 26.04.2022

Annexure A" as referred to in paragraph 2(h) of 'Report on Other Legal and Regulatory Requirement' Section to the Independent Auditor's reports of even date on the Financial Statements of Care Health Insurance Limited.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Care Health Insurance Limited** ("the Company") as of 31st March, 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013, including the provisions of the Insurance Act, 1938 as amended by the Insurance Laws (Amendment) Act 2015, Insurance Regulatory and Development Authority Act, 1999, the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002, as amended and the orders/directions and circulars issued by the Insurance Regulatory and Development Authority of India (IRDAI) in this regard to the extent applicable.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting with reference to these financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating

effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, adequate internal financial controls with reference to the financial statements and such internal financial controls with reference to the financial statements were operating effectively as at 31st March, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matter

The estimate of claims Incurred But Not Reported (IBNR) and Claims Incurred But Not Enough Reported (IBNER) have been certified by the Company's Appointed Actuary and have been relied upon by us as mentioned in 'Other Matter' Paragraph of our Audit Report on the financial statements for the year ended 31th March, 2022. Accordingly, our opinion on the internal financial controls with reference to the financial statements does

not include reporting on the adequacy and operating effectiveness of the internal controls over the quantum and accuracy of the aforesaid liabilities.

For and on behalf of
T R Chadha & Co LLP
Chartered Accountants
Firm Regn. No. 006711N/N500028

For and on behalf of
S. P. Chopra & Co.
Chartered Accountants
Firm Regn. No.000346N

Hitesh Garg
Partner
M. No. 502955

Place: New Delhi
Date: 26.04.2022

Gautam Bhutani
Partner
M. No. 524485

Place: New Delhi
Date: 26.04.2022

Annexure 'B', as referred to in paragraph 3 of 'Report on other Legal and Regulatory Requirements' Section to the Independent Auditor's Report of even date on the Financial Statements of Care Health Insurance Limited

Independent Auditor's Certificate

This certificate is issued to comply with the provisions of paragraph 4 of Schedule C of the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations 2002, (the "Regulations") read with regulation 3 of the Regulations.

Management's Responsibility

The Company's Board of Directors is responsible for complying with the provisions of the Insurance Act, 1938, as amended by the Insurance Laws (Amendment) Act 2015, the Insurance Regulatory and Development Authority Act, 1999, the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002, as amended, and the orders/directions issued by the Insurance Regulatory and Development Authority of India (the "IRDAI") in this regard, which includes the preparation of the Management Report. This includes collecting, collating and validating data and designing, implementing and monitoring of internal controls suitable for ensuring compliance as aforesaid.

Auditor's Responsibility

Pursuant to the requirements, it is our responsibility to obtain reasonable assurance and form an opinion based on our audit and examination of books and records as to whether the Company has complied with the matters contained in paragraph 4 of Schedule C of the Regulations read with regulation 3 of Regulations.

We audited the financial statements of the Company as of and for the financial year ended 31st March, 2022 on which we issued an unmodified audit opinion vide our report dated 26th April, 2022. Our audit of these financial statements was conducted in accordance with the Standards on Auditing and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India ('ICAI'). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. Our audit was not planned and performed in connection with any transactions to identify matters that may be of potential interest to third parties.

We conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) (the 'Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI').

The Guidance Note requires that we comply with the independence and other ethical requirements of the Code of ethics issued by the ICAI. We have complied with the relevant applicable requirements of the Standard on Quality Control ('SQC') 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services engagements.

Opinion

In accordance with information and explanations given to us and to the best of our knowledge and belief and based on our examination of the books of account and other records maintained by the Company for the year ended 31st March, 2022, we certify that:

1. We have verified the cash balances maintained by the Company, to the extent considered necessary. As regards the securities relating to the Company's investments as at 31st March, 2022, the same have been verified on the basis of the dematerialized statement / confirmations received from the custodian;
2. The Company is not a trustee of any trust; and
3. No part of the assets of the policyholders' funds has been directly or indirectly applied in contravention to the provisions of the Insurance Act, 1938, as amended by the Insurance Laws (Amendment) Act, 2015, relating to the application and investments of the policyholders' funds.

Restriction to use

This certificate is addressed to and provided to the Board of Directors of the Company, solely for inclusion in the annual accounts of the Company as per the Regulations and should not be used by any other person or for any other purpose. We have no responsibility to update this certificate for events and circumstances occurring after the date of this certificate. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For and on behalf of
T R Chadha & Co LLP
Chartered Accountants
Firm Regn. No. 006711N/N500028

For and on behalf of
S. P. Chopra & Co.
Chartered Accountants
Firm Regn. No.000346N

Hitesh Garg
Partner
M. No. 502955

Gautam Bhutani
Partner
M. No. 524485

Place: New Delhi
Date: 26.04.2022

Place: New Delhi
Date: 26.04.2022

FORM B-RA

MISCELLANEOUS BUSINESS REVENUE ACCOUNT FOR THE YEAR ENDED 31st MARCH, 2022

S. No	Particulars	Schedule	For the Year ended 31st March, 2022	For the Year ended 31st March, 2021
			(₹ '000)	(₹ '000)
1	Premiums earned (Net)	1	25,108,423	17,294,69
2	Profit/ loss on sale/redemption of Investments		36,367	19,82
3	Others			
	- Contribution from the Shareholders' Account towards Excess EOM		3,186,972	2,402,14
4	Interest, Dividend & Rent – Gross		1,286,113	1,039,66
	TOTAL (A)		29,617,875	20,756,32
1	Claims incurred (Net)	2	16,337,330	9,538,16
2	Commission	3	1,101,665	266,08
3	Operating expenses related to Insurance business	4	10,708,139	7,210,41
4	Premium deficiency		(1,358,782)	1,114,22
	TOTAL (B)		26,788,352	18,128,88
	Operating profit/(loss) from Miscellaneous business C= (A - B)		2,829,523	2,627,43
	APPROPRIATIONS			
	Transfer to Shareholders' account		2,829,523	2,627,43
	Transfer to catastrophe reserve		-	-
	Transfer to other reserves		-	-
	TOTAL (C)		2,829,523	2,627,43
	Significant Accounting Policies and Notes to Accounts	16		

* Expense in excess of the limit allowed as per regulation on expenses of management charged to shareholder's account (Refer note 26)

The schedules referred to above form an integral part of the Financial Statements.

For T.R. Chadha & Co. LLP
Chartered Accountants
Firm Regn No. : 006711N/N500028

For S.P. Chopra & Co.
Chartered Accountants
Firm Regn No. : 000346N

For and on behalf of Board of Directors

Dr. Rashmi Saluja
Non-Executive Chairperson
(DIN 01715298)

Anuj Gulati
Managing Director & CEO
(DIN 00278955)

Hitesh Garg
Partner
Membership No. :502955

Gautam Bhutani
Partner
Membership No. : 524485

Shamsher Singh Mehta
Non-Executive
Independent Director
(DIN 02201929)

Pankaj Gupta
Chief Financial Officer

Place: Gurugram
Date: 26th April, 2022

Pratik Kapoor
Company Secretary

Ambrish Jindal
Head-Finance & Accounts

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH, 2022

S. No	Particulars	Schedule	For the Year ended 31st March, 2022 (₹ '000)	For the Year ended 31st March, 2021 (₹ '000)
1	OPERATING PROFIT/(LOSS)			
	(a) Fire Insurance		-	-
	(b) Marine Insurance		-	-
	(c) Miscellaneous Insurance		2,829,523	2,627,439
2	INCOME FROM INVESTMENTS			
	(a) Interest, Dividend & Rent – Gross		590,837	568,426
	(b) Profit on sale of investments		18,896	24,456
	Less: Loss on sale of investments		(25,697)	-
3	OTHER INCOME			
	(a) Provision no longer required written back		-	8,232
	TOTAL (A)		3,413,559	3,228,553
4	PROVISIONS (Other than taxation)			
	(a) For diminution in the value of investments		-	-
	(b) For doubtful debts		-	-
	(c) Others		-	-
5	OTHER EXPENSES			
	(a) Expenses other than those related to Insurance Business		45,944	45,571
	(b) Bad debts written off		6,956	7,636
	(c) Foreign Exchange Loss/(Gain)		5,028	10,094
	(d) Corporate Social Responsibility (CSR) Expenses		13,214	7,111
	(e) Sandbox related expenses		-	1,146
	(f) Contribution to the Policyholders' Fund towards Excess EOM		3,186,972	2,402,144
	TOTAL (B)		3,258,114	2,473,702
	Profit / (Loss) Before Tax		155,445	754,851
	Provision for Taxation		-	-
	- Current tax		-	154,161
	-Tax relating to earlier years		18,442	-
	-Deferred Tax Expense/(Income)		22,073	(421,600)
	Profit / (Loss) After Tax		114,930	1,022,290
	APPROPRIATIONS			
	(a) Interim dividends paid during the year		-	-
	(b) Proposed final dividend		-	-
	(c) Dividend Distribution Tax		-	-
	(d) Transfer to any Reserves or Other Accounts		-	-
	Balance of profit/ loss brought forward from last year/period		(933,289)	(1,955,579)
	Balance carried forward to Balance Sheet		(818,359)	(933,289)
	Significant Accounting Policies and Notes to Accounts	16		

* Expense in excess of the limit allowed as per regulation on expenses of management charged to shareholder's account (Refer note 26)

The schedules referred to above form an integral part of the Financial Statements.

For T.R. Chadha & Co. LLP

Chartered Accountants

Firm Regn No. : 006711N/N500028

For S.P. Chopra & Co.

Chartered Accountants

Firm Regn No. : 000346N

For and on behalf of Board of Directors

Dr. Rashmi Saluja
Non-Executive Chairperson
(DIN 01715298)

Anuj Gulati
Managing Director & CEO
(DIN 00278955)

Hitesh Garg
Partner
Membership No. :502955

Gautam Bhutani
Partner
Membership No. : 524485

Shamsher Singh Mehta
Non-Executive
Independent Director
(DIN 02201929)

Pankaj Gupta
Chief Financial Officer

Place: Gurugram
Date: 26th April, 2022

Pratik Kapoor
Company Secretary

Ambrish Jindal
Head-Finance & Accounts

RECEIPTS AND PAYMENTS ACCOUNT FOR THE YEAR ENDED 31st MARCH, 2022

Particulars	For the Year ended 31st March, 2022	For the Year ended 31st March, 2021
	(₹ '000)	(₹ '000)
Cash Flows from the Operating activities:		
Premium received from policyholders, including advance receipts	46,958,994	30,236,732
Other receipts	-	-
Payments to the re-insurers, net of commissions and claims	2,335,715	(242,467)
Payments to co-insurers, net of claims recovery	26,609	(15,004)
Payments of claims	(20,731,816)	(10,983,424)
Payments of commission and brokerage	(4,760,484)	(3,150,355)
Payments of other operating expenses*	(12,270,706)	(8,749,191)
Preliminary and pre-operative expenses	-	-
Deposits, advances and staff loans	(46,730)	26,489
Income taxes paid (Net)	(77,821)	(102,909)
Service tax / GST paid	(4,758,642)	(3,227,784)
Other payments	-	-
Cash flows before extraordinary items	6,675,120	3,792,087
Cash flow from extraordinary operations	-	-
Net cash flow from Operating activities	6,675,120	3,792,087
Cash flows from Investing activities:		
Purchase of fixed assets (including capital advances)	(298,114)	(140,200)
Proceeds from sale of fixed assets	880	1,198
Purchases of investments	(11,363,488)	(10,502,712)
Loans disbursed	-	-
Sales of investments	-	2,260,000
Repayments received	3,082,239	-
Rents/Interests/ Dividends received	1,841,357	1,506,783
Investments in money market instruments and in liquid mutual funds (Net)	(1,134,501)	(382,505)
Expenses related to investments	-	-
Net cash flow from Investing activities	(7,871,627)	(7,257,436)
Cash flows from Financing activities:		
Proceeds from issuance of share capital	1,531,612	3,373,670
Proceeds from borrowing	-	-
Repayments of borrowing	-	-
Interest/dividends paid	-	-
Net cash flow from Financing activities	1,531,612	3,373,670
Effect of foreign exchange rates on cash and cash equivalents, net	(5,028)	(10,095)
Net increase in cash and cash equivalents:	330,076	(101,774)
Cash and cash equivalents at the beginning of the year	456,800	558,574
Cash and cash equivalents at the end of the year	786,876	456,800

*Includes payments towards Corporate Social Responsibility of Rs. 8,376 thousand (previous period: Rs. 7,111 thousand)

For T.R. Chadha & Co. LLP

Chartered Accountants

Firm Regn No. : 006711N/N500028

For S.P. Chopra & Co.

Chartered Accountants

Firm Regn No. : 000346N

For and on behalf of Board of Directors

Dr. Rashmi Saluja
Non-Executive Chairperson
(DIN 01715298)

Anuj Gulati
Managing Director & CEO
(DIN 00278955)

Hitesh Garg
Partner

Membership No. : 502955

Gautam Bhutani
Partner

Membership No. : 524485

Shamsher Singh Mehta
Non-Executive
Independent Director
(DIN 02201929)

Pankaj Gupta
Chief Financial Officer

Place: Gurugram
Date: 26th April, 2022

Pratik Kapoor
Company Secretary

Ambrish Jindal
Head-Finance & Accounts

FORM B-BS
BALANCE SHEET AS AT 31ST MARCH, 2022

Particulars	Schedule	As at 31st March, 2022	As at 31st March, 2021
SOURCES OF FUNDS		(₹ '000)	(₹ '000)
Share Capital	5	9,085,677	8,410,422
Share Application Money Pending Allotment		-	-
Reserves And Surplus	6	3,806,356	2,911,469
Fair Value Change Account - Shareholders' Funds		(5,671)	(19,836)
Fair Value Change Account - Policyholders' Funds		1,074	2,798
Borrowings	7	-	-
TOTAL		12,887,436	11,304,853
APPLICATION OF FUNDS			
Investments			
- Shareholders	8	11,056,379	9,098,394
- Policyholders	8A	24,604,390	17,251,666
Loans	9	-	-
Fixed Assets	10	550,719	489,986
Deferred Tax Asset*		399,577	421,600
CURRENT ASSETS			
Cash and Bank Balances	11	786,876	456,800
Advances and Other Assets	12	1,574,820	1,454,140
Sub-Total (A)		2,361,696	1,910,940
Current Liabilities	13	11,611,932	7,918,651
Provisions	14	15,291,702	10,882,371
Sub-Total (B)		26,903,634	18,801,022
Net Current Assets (C) = (A - B)		(24,541,938)	(16,890,082)
Miscellaneous Expenditure (To The Extent Not Written Off or Adjusted)	15	-	-
Debit Balance In Profit And Loss Account		818,359	933,289
TOTAL		12,887,436	11,304,853
Significant Accounting Policies and Notes to Accounts	16		
Contingent liabilities	16.1		

*Refer Note 24.

The schedules referred to above form an integral part of the Financial Statements.

For T.R. Chadha & Co. LLP
Chartered Accountants
Firm Regn No. : 006711N/N500028

For S.P. Chopra & Co.
Chartered Accountants
Firm Regn No. : 000346N

For and on behalf of Board of Directors

Dr. Rashmi Saluja
Non-Executive Chairperson
(DIN 01715298)

Anuj Gulati
Managing Director & CEO
(DIN 00278955)

Hitesh Garg
Partner
Membership No. :502955

Gautam Bhutani
Partner
Membership No. : 524485

Shamsher Singh Mehta
Non-Executive
Independent Director
(DIN 02201929)

Pankaj Gupta
Chief Financial Officer

Place: Gurugram
Date: 26th April, 2022

Pratik Kapoor
Company Secretary

Ambrish Jindal
Head-Finance & Accounts

SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 1

PREMIUM EARNED [NET]

Particulars	For the Year ended 31st March, 2022				For the Year ended 31st March, 2021			
	Health	PA	Other	Total	Health	PA	Other	Total
	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)
Premium from direct business written *	34,254,997	3,894,564	659,491	38,809,052	23,100,450	2,256,974	240,113	25,597,537
Add: Premium on reinsurance accepted	665,307	-	-	665,307	282,682	-	-	282,682
Less : Premium on reinsurance ceded	8,255,791	244,669	89,674	8,590,134	5,889,290	141,197	41,440	6,071,927
Net Premium	26,664,513	3,649,895	569,817	30,884,225	17,493,842	2,115,777	198,673	19,808,292
Adjustment for changes in reserve for unexpired risks	4,874,675	772,948	128,179	5,775,802	2,221,776	321,662	(29,841)	2,513,597
Total Premium Earned (Net)	21,789,838	2,876,947	441,638	25,108,423	15,272,066	1,794,115	228,514	17,294,695

* Net of GST

SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 2

CLAIMS INCURRED [NET]

Particulars	For the Year ended 31st March, 2022				For the Year ended 31st March, 2021			
	Health (₹ '000)	PA (₹ '000)	Other (₹ '000)	Total (₹ '000)	Health (₹ '000)	PA (₹ '000)	Other (₹ '000)	Total (₹ '000)
Claims paid								
Direct	20,122,840	428,307	242,680	20,793,827	10,525,404	312,022	136,947	10,974,373
Add : Re-insurance accepted	277,437	-	-	277,437	230,922	-	-	230,922
Less : Re-Insurance Ceded	6,173,483	50,920	93,845	6,258,248	2,804,992	44,104	51,263	2,880,419
Net Claims Paid	14,226,794	377,387	208,835	14,813,016	7,951,334	267,858	105,684	8,324,876
Add: Claims Outstanding at the end of the year *	4,414,605	565,724	382,793	5,363,122	3,098,499	492,688	247,621	3,838,808
Less: Claims Outstanding at the beginning of the year*	3,098,499	492,688	247,621	3,838,808	2,024,207	353,720	247,594	2,625,521
Total Claims Incurred	15,542,900	450,423	344,007	16,337,330	9,025,626	406,826	105,711	9,538,163

*Net of Reinsurance

SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 3

COMMISSION

Particulars	For the Year ended 31st March, 2022				For the Year ended 31st March, 2021			
	Health	PA	Other	Total	Health	PA	Other	Total
Commission Paid	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)	(₹ '000)
Direct	4,265,072	523,533	109,987	4,898,592	3,163,462	326,140	42,763	3,532,365
Add: Re-insurance Accepted	(34,786)	-	-	(34,786)	2,776	-	-	2,776
Less: Commission on Re-insurance Ceded	3,675,212	46,834	40,095	3,762,141	3,229,070	20,559	19,425	3,269,054
Net Commission	555,074	476,699	69,892	1,101,665	(62,832)	305,581	23,338	266,087

BREAK-UP OF THE EXPENSES(GROSS) INCURRED TO PROCURE BUSINESS

Agents	2,175,061	61,237	66,991	2,303,289	1,778,122	31,505	31,552	1,841,179
Brokers*	1,216,389	46,732	41,452	1,304,573	813,939	25,467	10,832	850,238
Corporate Agency	873,622	415,564	1,544	1,290,730	571,401	269,168	379	840,948
Referral	-	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-	-
Total	4,265,072	523,533	109,987	4,898,592	3,163,462	326,140	42,763	3,532,365

* Includes Web-Aggregator.

SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 4

OPERATING EXPENSES RELATED TO INSURANCE BUSINESS

S. No	Particulars	For the Year ended 31st March, 2022				For the Year ended 31st March, 2021			
		Health (₹ '000)	PA (₹ '000)	Other (₹ '000)	Total (₹ '000)	Health (₹ '000)	PA (₹ '000)	Other (₹ '000)	Total (₹ '000)
1	Employees' remuneration & welfare benefits	5,422,457	532,283	106,773	6,061,513	3,891,793	328,318	42,315	4,262,426
2	Travel, conveyance and vehicle running expenses	83,178	8,165	1,630	92,973	28,027	2,364	305	30,696
3	Training expenses	119,442	11,725	2,352	133,519	66,379	5,600	722	72,701
4	Rents, rates & taxes	157,915	15,501	3,109	176,525	133,404	11,254	1,450	146,108
5	Repairs	5,666	556	112	6,334	7,268	613	79	7,960
6	Printing & stationery	56,348	5,531	1,110	62,989	40,145	3,387	437	43,969
7	Communication expenses	120,825	11,861	2,379	135,065	124,028	10,463	1,349	135,840
8	Legal & professional charges	198,333	19,469	3,905	221,707	183,007	15,439	1,990	200,436
9	Auditors' fees, expenses etc								
	(a) as auditor	4,267	419	84	4,770	4,190	354	46	4,590
	(b) as adviser or in any other capacity, in respect of								
	(i) Taxation matters	-	-	-	-	-	-	-	-
	(ii) Insurance matters	-	-	-	-	-	-	-	-
	(iii) Management services; and	-	-	-	-	-	-	-	-
	(c) in any other capacity	-	-	-	-	-	-	-	-
10	Advertisement and publicity	2,684,624	263,530	52,863	3,001,017	1,532,292	129,267	16,661	1,678,220
11	Interest & bank charges	93,838	9,211	1,848	104,897	72,256	6,096	786	79,138
12	Others	-	-	-	-	-	-	-	-
	(a) Electricity and Water	27,336	2,683	538	30,557	21,844	1,843	238	23,925
	(b) Brand/Trade Mark usage fee/charges	-	-	-	-	-	-	-	-
	(c) Business Development and Sales Promotion Expenses	6,458	634	127	7,219	7,810	659	85	8,554
	(d) Information Technology Expenses	243,972	23,949	4,804	272,725	192,405	16,232	2,092	210,729
	(e) Other	144,161	14,151	2,839	161,151	91,664	7,733	997	100,394
13	Depreciation	203,055	19,932	3,998	226,985	180,775	15,250	1,966	197,991
14	Goods and Services Tax (GST)	7,322	719	144	8,185	6,155	519	67	6,741
	TOTAL	9,579,197	940,319	188,623	10,708,139	6,583,442	555,391	71,585	7,210,418

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 5****SHARE CAPITAL**

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Authorised Capital		
	1,300,000,000 Equity Shares of ₹ 10 each (Previous Year 1,300,000,000 Equity Shares of ₹ 10 each)	13,000,000	13,000,000
2	Issued Capital		
	908,567,736 Equity Shares of ₹ 10 each (Previous Year 841,042,196 Equity Shares of Rs 10 each)	9,085,677	8,410,422
3	Subscribed Capital		
	908,567,736 Equity Shares of ₹ 10 each (Previous Year 841,042,196 Equity Shares of Rs 10 each)	9,085,677	8,410,422
4	Called-up Capital		
	908,567,736 Equity Shares of ₹ 10 each (Previous Year 841,042,196 Equity Shares of Rs 10 each)	9,085,677	8,410,422
	Less : Calls unpaid	-	-
	Add : Equity Shares forfeited (Amount originally paid up)	-	-
	Less : Par Value of Equity Shares bought back	-	-
	Less : Preliminary Expenses	-	-
	Less : Expenses including commission or brokerage on Underwriting or subscription of shares	-	-
	TOTAL	9,085,677	8,410,422

Notes:

- 1 Out of the above, 594,732,253 (Previous Year 594,732,253) Equity Shares of ₹ 10 each are held by the holding company "Religare Enterprises Limited", along with its nominees.

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012



SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 5A

PATTERN OF SHAREHOLDING

[As certified by the Management]

Shareholder	As at 31st March, 2022		As at 31st March, 2021	
	Number of Shares	% of Holding	Number of Shares	% of Holding
Promoters				
· Indian	795,835,614	87.6%	795,835,614	94.6%
· Foreign	-	-	-	-
Others	112,732,122	12.4%	45,206,582	5.4%
TOTAL	908,567,736	100.0%	841,042,196	100.0%

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 6****RESERVES AND SURPLUS**

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Capital Reserve	-	-
2	Capital Redemption Reserve	-	-
3	Share Premium		
	- Opening Balance	2,614,844	191,306
	- Additions during the year	1,154,369	2,423,538
4	General Reserves	-	-
	Less: Debit balance in the Profit & Loss Account	-	-
	Less: Amount utilized for Buy-back	-	-
5	Catastrophe Reserve	-	-
6	Other Reserves		
	- Employee Stock Option Reserve		
	- Opening Balance	296,625	363,550
	- Additions during the year	38,530	111,622
	- Deduction during the year	(298,012)	(178,547)
7	Balance of Profit in Profit & Loss Account	-	-
	TOTAL	3,806,356	2,911,469

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 7****BORROWINGS**

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Debentures/ Bonds	-	-
2	Banks	-	-
3	Financial Institutions	-	-
4	Others	-	-
	TOTAL	-	-

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012



SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 8

INVESTMENTS - SHAREHOLDERS

S. No	Particulars	Shareholders	
		As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
LONG TERM INVESTMENTS			
1	Government securities and Government guaranteed bonds including Treasury Bills	2,309,776	2,373,822
2	Other Approved Securities	152,761	218,873
3	Other Investments		
	(a) Shares	-	-
	(aa) Equity	684,390	15,415
	(bb) Preference	-	-
	(b) Mutual Funds	-	-
	(c) Derivative Instruments	-	-
	(d) Debentures/ Bonds	1,538,919	1,809,695
	(e) Other Securities	-	-
	(f) Subsidiaries	-	-
	(g) Investment Properties-Real Estate	-	-
4	Investments in Infrastructure and Social Sector	3,356,309	4,028,036
5	Other than Approved Investments	145,797	51,905
SHORT TERM INVESTMENTS			
1	Government securities and Government guaranteed bonds including Treasury Bills	49,661	200,981
2	Other Approved Securities	65,126	-
3	Other Investments		
	(a) Shares		
	(aa) Equity	-	-
	(bb) Preference	-	-
	(b) Mutual Funds	1,033,523	-
	(c) Derivative Instruments	-	-
	(d) Debentures/ Bonds	269,405	349,667
	(e) Other Securities	-	-
	-Fixed Deposit	800,000	
	(f) Subsidiaries	-	-
	(g) Investment Properties-Real Estate	-	-
4	Investments in Infrastructure and Social Sector	650,712	50,000
5	Other than Approved Investments	-	-
	TOTAL	11,056,379	9,098,394
INVESTMENTS			
1	In India	11,056,379	9,098,394
2	Outside India	-	-
	TOTAL	11,056,379	9,098,394

Note:

Aggregate amount of Company's investments other than listed equity securities and derivative instruments is Rs.10,286,512 Thousands (Previous year Rs. 9,082,979 Thousands). Market value of such investments as at 31st March, 2022 is Rs. 10,336,510 Thousands (Previous year Rs. 9,284,266 Thousands).

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012



SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 8A

INVESTMENTS - POLICYHOLDERS

S. No	Particulars	Policy-Holders	
		As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
	LONG TERM INVESTMENTS		
1	Government securities and Government guaranteed bonds including Treasury Bills	7,060,004	4,536,107
2	Other Approved Securities	854,363	1,006,956
3	Other Investments		
	(a) Shares		
	(aa) Equity	-	-
	(bb) Preference	-	-
	(b) Mutual Funds	-	-
	(c) Debentures/ Bonds	4,106,027	2,597,266
	(d) Investment Properties-Real Estate	-	-
	(e) Other Securities	-	-
4	Investments in Infrastructure and Housing	8,550,956	5,417,246
	Sub-Total	20,571,350	13,557,575
	SHORT TERM INVESTMENTS		
1	Government securities and Government guaranteed bonds including Treasury Bills	600,454	150,267
2	Other Approved Securities	150,080	-
3	Other Investments		
	(a) Shares		
	(i) Equity	-	-
	(ii) Preference	-	-
	(b) Mutual Funds	633,517	1,361,244
	(c) Debentures/ Bonds	1,248,466	635,407
	(d) Investment Properties-Real Estate	-	-
	(e) Other Securities	-	-
4	Investments in Infrastructure and Housing	1,400,521	1,547,173
	Sub-Total	4,033,038	3,694,091
	TOTAL	24,604,388	17,251,666
	INVESTMENTS		
1	In India	24,604,388	17,251,666
2	Outside India	-	-
	TOTAL	24,604,388	17,251,666

Notes:

Aggregate amount of Company's investments other than listed equity securities and derivative instruments is Rs.24,604,388 Thousands (Previous year Rs.17,251,666 Thousands). Market value of such investments as at 31st March, 2022 is Rs.24,746,626 Thousands (Previous year Rs.17,790,611 Thousands).

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012



SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 9

LOANS

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	SECURITY-WISE CLASSIFICATION		
	Secured		
	(a) On mortgage of property		
	(aa) In India		
	(bb) Outside India		
	(b) On Shares, Bonds, Govt. Securities		
	(c) Others		
	Unsecured		
	TOTAL	-	-
2	BORROWER-WISE CLASSIFICATION		
	(a) Central and State Governments		
	(b) Banks and Financial Institutions		
	(c) Subsidiaries		
	(d) Industrial Undertakings		
	(e) Others		
	TOTAL	-	-
3	PERFORMANCE-WISE CLASSIFICATION		
	(a) Loans classified as standard		
	(aa) In India		
	(bb) Outside India		
	(b) Non-performing loans less provisions		
	(aa) In India		
	(bb) Outside India		
	TOTAL	-	-
4	MATURITY-WISE CLASSIFICATION		
	(a) Short Term		
	(b) Long Term		
	TOTAL	-	-

SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

(₹ '000)

Cost/ Gross Block				Depreciation				Net Block	
As at 1st April, 2021	Additions	Deductions	As at 31st March, 2022	Upto 1st April, 2021	For the period	On Sales / Adjustments	Upto 31st March, 2022	As at 31st March, 2022	As at 31st March, 2021
-	-	-	-	-	-	-	-	-	-
1,001,462	101,667	-	1,103,129	710,939	134,582	(28)	845,550	257,579	290,523
-	-	-	-	-	-	-	-	-	-
24,281	226	1,936	22,571	12,639	1,246	1,615	12,271	10,300	11,642
-	-	-	-	-	-	-	-	-	-
11,006	5,279	368	15,916	10,810	1,681	329	12,162	3,754	196
416,701	162,439	8,419	570,721	276,883	73,599	8,201	342,281	228,439	139,817
3,733	-	1,788	1,945	3,733	-	1,788	1,945	-	-
76,016	19,200	6,971	88,246	47,892	15,878	6,513	57,256	30,989	28,124
-	-	-	-	-	-	-	-	-	-
1,533,199	288,811	19,482	1,802,528	1,062,897	226,986	18,417	1,271,466	531,063	470,302
1,406,552	138,028	11,381	1,533,199	876,002	197,991	11,096	1,062,897	470,302	-
19,684	18,696	18,723	19,656	-	-	-	-	19,656	19,684
-	-	-	-	-	-	-	-	-	-
1,552,883	307,507	38,205	1,822,185	1,062,897	226,986	18,417	1,271,466	550,719	489,986
1,421,213	157,712	26,042	1,552,883	876,002	197,991	11,096	1,062,897	489,986	-

leases taken on long term lease by company

As per Schedule-II to Companies Act, 2013. Useful Life of softwares has been considered as 74 months; with effect from October 2019, useful life of software enhancements has been considered as 36 Months. Useful life of some assets determined lower than that recommended by the Schedule - II to Companies Act, 2013.

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 11****CASH AND BANK BALANCES**

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Cash (including cheques, drafts and stamps)	43,857	45,816
2	Bank Balances		
	(a) Deposit Accounts [^]		
	(aa) Short-term (due within 12months)	7,531	9,244
	(bb) Others	4,833	2,500
	(b) Current Accounts	730,655	399,240
	(c) Others	-	-
3	Money at Call and Short Notice		
	(a) With Banks	-	-
	(b) With other Institutions	-	-
4	Others	-	-
	TOTAL	786,876	456,800
	Balances with non-scheduled banks included in 2 and 3 above	NIL	NIL

[^] Investment related Fixed deposits have been reported under Investments instead of cash and Bank balance.

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012



SCHEDULES FORMING PART OF FINANCIAL STATEMENTS

SCHEDULE - 12

ADVANCES AND OTHER ASSETS

S. No	Particulars	As at 31st March, 2022	As at 31st March, 2021
		(₹ '000)	(₹ '000)
	ADVANCES		
1	Reserve deposits with ceding companies	-	-
2	Application money for investments	-	-
3	Prepayments	128,761	87,986
4	Advances to directors/officers	-	-
5	Advance tax paid and taxes deducted at source (Net of provision for taxation)	23,625	-
6	Others		
	(a) Advances to suppliers	27,937	79,839
	(b) Other Advances/ Receivables	26,882	17,699
	TOTAL (A)	207,205	185,524
	OTHER ASSETS		
1	Income accrued on investments *	903,472	734,530
2	Outstanding premiums	73,090	73,090
	Less : Provisions for doubtful debts	(73,090)	(73,090)
3	Agents balances	20,403	20,956
4	Foreign agencies balances	-	-
5	Due from other entities carrying on insurance business (including re-insurers)	287,364	394,292
	Less : Provisions for doubtful debts	(13,083)	(13,083)
6	Due from subsidiaries/holding companies	-	-
7	Deposit with RBI (Pursuant to section 7 of Insurance Act, 1938)	-	-
8	Others		
	(a) Rent Deposits & other assets	130,773	106,341
	(b) Unclaimed Amount of Policyholder (Investment)	35,550	22,967
	(c) Income on Unclaimed amount of Policy Holder (Investment)	3,136	2,613
	TOTAL (B)	1,367,615	1,268,616
	TOTAL (A+B)	1,574,820	1,454,140

* Income accrued on investments includes interest on deposits also.

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 13****CURRENT LIABILITIES**

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Agents' balances	393,612	255,335
2	Balance due to other insurance companies	453,034	111,430
3	Deposits held on re-insurance ceded	-	-
4	Premiums received in advance	2,029,748	571,986
5	Unallocated premium	485,401	793,270
6	Sundry creditors	1,856,860	1,776,435
7	Due to subsidiaries/holding company	479	2,658
8	Claims outstanding*	5,363,122	3,838,808
9	Due to officers/directors	-	-
10	Unclaimed amount of Policy Holder	34,330	22,333
11	Others		
	(a) Tax deducted payable	545,385	200,792
	(b) Other statutory dues	20,980	17,573
	(c) GST Liabilities (Net)	417,611	317,257
	(d) Income on Unclaimed amounts on Policyholder (Investments)	3,136	2,613
	(e) Other Liabilities	8,234	8,161
	TOTAL	11,611,932	7,918,651

*Net of Reinsurance

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 14****PROVISIONS**

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Reserve for unexpired risk	15,168,581	9,392,779
2	For taxation (less advance tax paid and tax deducted at source)	-	42,964
3	For proposed dividends	-	-
4	For dividend distribution tax	-	-
5	Others		
	(a) Lease equalisation reserve	588	8,375
	(b) For Employee Benefits	122,533	79,471
6	Reserve for Premium Deficiency	-	1,358,782
	TOTAL	15,291,702	10,882,371

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

**SCHEDULES FORMING PART OF FINANCIAL STATEMENTS****SCHEDULE - 15****MISCELLANEOUS EXPENDITURE**

(To the extent not written off or adjusted)

S. No	Particulars	As at 31st March, 2022 (₹ '000)	As at 31st March, 2021 (₹ '000)
1	Discount allowed in issue of shares/ debentures	-	-
2	Others	-	-
	TOTAL	-	-

Schedule 16

Significant Accounting Policies forming part of the financial statements for the year ended 31st March, 2022

1. Background

Care Health Insurance Limited (formerly known as Religare Health Insurance Company Limited) ("the Company") was incorporated on 2nd April, 2007 as a company under the Companies Act, 2013 (erstwhile the Companies Act, 1956) ('the Act'). The Company is licensed since 26th April, 2012 by the Insurance Regulatory and Development Authority ('IRDA') for carrying out the business of underwriting General insurance relating to Health segment, which comprises Health, Personal Accident and Travel insurance. These products are distributed through individual agents, brokers, corporate agents, online and Company's sales force.

2. Basis of Preparation of Financial Statements

The financial statements have been prepared and presented on a going concern basis, under the historical cost convention and on accrual basis of accounting, unless otherwise specifically stated, and in accordance with the generally accepted accounting principles, and the applicable provisions of the Insurance Act, 1938, as amended by the Insurance Laws (Amendment) Act, 2015, the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002 (the 'Regulations') and orders / directions, circulars/notifications and guidelines issued by the Insurance Regulatory and Development Authority of India ('IRDAI') in this behalf from time to time, and the Companies Act, 2013, and comply with the applicable Accounting Standards (AS) specified under Section 133 of the Companies Act, 2013 (the 'Act') read with the Companies (Accounting Standards) Rules, 2014, as amended, and to the extent applicable and current practices prevailing within the Insurance Industry in India. Accounting policies have been consistently applied to the extent applicable, and in case of any change, the same is disclosed appropriately in the manner so required.

3. Use of estimates

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosure and the disclosure of contingent liabilities.

These estimates and assumptions are based on the facts and events, that existed as at the date of Balance Sheet, or that occurred after that date but provide additional evidence about conditions existing as at the Balance Sheet date. Any revision to the accounting estimates is recognized prospectively in the current and future period/s.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)
IRDA Registration number 148 dated 26 April, 2012



4. Significant Accounting Policies

4.1. Revenue recognition

Premium income

Premium (Net of Goods and Service Tax) is recognized as income over the contract period or period of risk, on the commencement of risk. In case of government scheme / policy, the premium is recognized to the extent of certainty of its realization. Any subsequent revisions to premium and adjustments on cancellation of policies are recognized in the year / period in which they occur.. The Net Premium Written (Net of Reinsurance ceded) is adjusted / netted of by the amount of movement of Unearned Premium Reserve to arrive at the net premium earned. The premium on insurance policies issued on installment basis is recognized as and when the installment premium is received subject to above principles.

Income from reinsurance business

Commission on reinsurance ceded is adjusted / netted off from commission expense in the period of ceding the risk.

Profit Commission under reinsurance treaties, wherever applicable, is recognized as income in the year of final determination of profits and combined with commission on reinsurance ceded.

Income earned on investments

Interest income on investments is recognized on accrual basis. Accretion of discount and amortization of premium relating to debt securities is recognized over the holding/maturity period on a straight-line basis. Realized gain/loss on securities, which is the difference between the sale consideration and the carrying value in the books of the Company, is recognized on the trade date. In determining the realized gain/loss, cost of securities is arrived at on 'Weighted average cost' basis. Further, in case of mutual funds and listed equity shares, the profit or loss on sale also includes the accumulated changes in the fair value previously recognized under 'Fair Value Change Account'. Sale consideration for the purpose of realized gain/loss is net of brokerage and taxes, if any, and excludes interest received on sale.

Dividend income is recognized when the right to receive dividend is established.

Investment income on shareholder funds is disclosed in Profit & Loss Account and investment income on policyholder funds is disclosed under Revenue Accounts.

4.2. Premium received in advance

Premium received in advance is the premium, where the period of inception of the cover sought is clearly outside the accounting period.

4.3. Unallocated Premium

Unallocated premium includes premium deposit and premium which has been received but for which risk has not commenced.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)
IRDA Registration number 148 dated 26 April, 2012



4.4. Reinsurance

Premium Ceded

Insurance premium on ceding of the risk is recognised in the period in which the risk commences in accordance with reinsurance arrangements with the reinsurers. Any subsequent revision to premium ceded is recognised in the period of such revision. Adjustment to reinsurance premium arising on cancellation of policies is recognized in the period in which they are cancelled. Premium on excess of loss reinsurance cover is accounted as premium ceded as per the reinsurance arrangements.

Re-Insurance acceptance

The results of a reinsurance accepted are accounted as per the last available statement of accounts/confirmation from reinsurers.

4.5. Premium Deficiency

Premium deficiency is recognised when the sum of expected claim costs and related expenses and maintenance costs exceed the reserve for unexpired risks and is computed based on actuarially determined ultimate loss ratios.

4.6. Unearned Premium Reserve

Unearned Premium Reserve represents that part of the net premium written (i.e. premium net of reinsurance ceded) which is attributable to, and set aside for subsequent risk to be borne by the Company under contractual obligation on contract period basis, whichever is appropriate and allocated to succeeding accounting periods and is created at 50% of the net premium written (excluding policies where the premium is earned fully during the accounting period i.e. expired policies) of preceding twelve months as at the Balance Sheet date.

4.7. Claims

Claims incurred represents claims paid, estimated liability for outstanding claims made following a loss occurrence reported and estimated liability for Claims Incurred but not reported (IBNR) and Claims Incurred but not enough reported (IBNER). It also includes specific claims settlement costs such as survey / legal / TPA fees and other directly attributable costs.

Claims are recognized as and when reported. Claims are recorded in the Revenue Account, net of claims recoverable from reinsurers / co-insurers to the extent there is a reasonable certainty of realization. These estimates are progressively revalued on the availability of further information. Estimated liability in respect of claims is provided for, based on the intimations received up to the year end, information / estimates provided by the insured / surveyors / Third Party Administrators (TPA) and judgment based on the past experience and other applicable laws and practices.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)

IRDA Registration number 148 dated 26 April, 2012



Claims Incurred but not reported (IBNR) represents that amount of claims that may have been incurred prior to the end of the current accounting year but have not been reported or claimed. The IBNR provision also includes provision, if any, required for claims Incurred but not enough reported (IBNER). IBNR and IBNER liabilities are provided based on actuarial principles and certified annually by the Appointed Actuary of the Company. The methodology and assumptions on the basis of which the liability has been determined has also been certified by the Appointed Actuary to be appropriate, in accordance with guidelines and norms issued by the Institute of Actuaries of India and in concurrence with the IRDAI.

4.8. Acquisition costs

Acquisition costs are those costs that vary with, and are primarily related to the acquisition of new and renewal of insurance contracts viz. commission, rewards and remuneration etc. These costs are expensed in the period in which they are incurred.

4.9. Investments

Investments are made in accordance with the Insurance Act, 1938, as amended, and Insurance Regulatory and Development Authority (Investment) Regulations, 2016, and other circulars/notifications and amendments issued by the IRDAI in this context from time to time.

Investments are recorded at cost, on trade date and includes brokerage, transfer charges, stamps etc., if any, and exclude interest accrued up to the date of purchase.

Classification

Investments maturing within twelve months from Balance Sheet date and Investments made with the specific intention to dispose off within twelve months are classified as 'short term investments'. Investments other than 'short term investments' are classified as 'long term investments'.

Investments that are earmarked, are allocated separately to policyholder's or shareholder's, as applicable; Investments other than earmarked, are segregated at Shareholder's level and Policyholder's level notionally based on policyholder's funds and shareholder's funds as of year end, as prescribed by IRDAI.

Valuation

Investments are valued as follows:

- **Debt securities and non-convertible preference shares**

All debt securities including government securities and non – convertible preference shares are considered as 'held to maturity' and accordingly stated at historical cost, subject to accretion of discount or amortization of premium over the holding/maturity period on a straight line basis.

- **Mutual funds**

Mutual fund investments are stated at fair value, being the closing net asset value at Balance Sheet date.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)

IRDA Registration number 148 dated 26 April, 2012



- **Listed Equities**

Listed equity shares are stated at fair value, being the quoted closing price on the Primary Exchange – 'National Stock Exchange ('NSE')' as at the Balance Sheet date. In case the equity share is not listed / traded on the Primary Exchange the quoted closing price on the Secondary Exchange – 'Bombay Stock Exchange ('BSE')', is considered as fair value. Equity shares awaiting listing are stated at historical cost subject to provision for diminution, if any, in the value of such investment determined separately for each individual investment.

- Investments other than mentioned above are valued at cost.

- **Fair Value Change Account**

In accordance with the Regulations, unrealized gain/loss arising due to changes in fair value of listed equity shares and mutual fund investments are taken to the 'Fair Value Change Account'. The balance in the Fair Value Change Account is not available for distribution.

Impairment of Investments

The Company assesses at each Balance Sheet date whether there is any indication of investments being impaired. If any such indication exists, the carrying value of such investment is reduced to its recoverable amount and the impairment loss is recognized in the Profit and Loss Account. If at the Balance Sheet date there is any indication that a previously assessed impairment loss no longer exists, then such loss is reversed and the investment is restated to that extent.

4.10. Fixed assets, Intangible and Impairments

Fixed assets and depreciation

Fixed assets are stated at cost less accumulated depreciation. Cost includes the purchase price and any cost directly attributable to bringing the asset to its working condition for its intended use.

Immovable assets at the leased premises including civil works, electrical items are capitalized as leasehold improvements and are amortized over the primary period of lease.

Depreciation is provided on Straight Line Method, over the useful life of the assets estimated by the management, in the manner prescribed in Schedule II of the Companies Act, 2013. The useful lives in the following cases are different from that prescribed by Schedule II of the Companies Act, 2013.

Assets Description	Useful Life of Assets prescribed as per Schedule II of the Companies Act, 2013 (No. of Years)	Useful Lives of the Assets as assessed/estimated by the Management (No. of Years)
Office Equipment (Glow Sign Boards and Batteries)	5	3
Furniture and Fixtures	10	5
Vehicles (acquired from November, 2011 to March, 2014)	8	6.25

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)

IRDA Registration number 148 dated 26 April, 2012



Based on usage pattern and internal assessment, the management believes that the useful lives as given above best represent the period over which the management expects to use these assets. Hence the useful life of these assets is different from the lives as prescribed in Schedule II of the Companies Act, 2013.

Depreciation on addition or on sale / discard of an asset is calculated pro-rata from / up to the date of such addition or sale/discard.

The asset's residual values, useful lives and method of depreciation are reviewed at the end of each reporting period and necessary adjustments are made accordingly, wherever required.

Gains or losses arising on retirement or disposal of fixed assets are recognized in the Revenue Account and/or Profit and Loss Account.

Intangible Assets

Intangible assets are recognized only if it is probable that the future economic benefits that are attributable to assets will flow to the Company and the costs of the assets can be measured reliably.

Intangible assets comprising computer software are carried at cost less amortization. Computer software including improvements are amortised over the management's estimate of the useful life of such intangibles. Management estimates for useful life of intangibles is 6 years 2 months. In case where an enhancement is done on existing computer software which results in improvement in useful life of the software, the Management estimates for useful life of these software enhancements is 3 years.

All assets including intangibles individually costing up to Rs. 5,000 are fully depreciated / amortized in the year in which they are acquired.

Capital Work in Progress

Capital work in progress includes assets not ready for the intended use and are carried at cost, comprising direct cost and related incidental expenses.

Impairment of assets

The Company assesses at each Balance Sheet date whether there is any indication that any asset may be impaired. If any such indication exists, the carrying value of such assets is reduced to its recoverable amount and the impairment loss is recognized in the Revenue Account and Profit and Loss Account. If, at the Balance Sheet date there is any indication that a previously assessed impairment loss no longer exists, then such loss is reversed and the asset is restated to that extent.

4.11. Operating Lease

Leases where a significant portion of the risks and rewards of the ownership are retained by the lessor are classified as Operating Leases. Lease payments of assets/premises taken on operating lease are recognised as an expense in the Revenue and/or Profit and Loss Account over the lease term on straight line basis.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)
IRDA Registration number 148 dated 26 April, 2012



4.12. Employee benefits

Short term employee benefits

All Employee benefits payable within twelve months of rendering the services are classified as short term benefits. Such benefits include salaries, bonus, awards, ex-gratia, performance incentive/pay etc. and the same are recognized in the period in which the employee renders the related services.

Post-Employment Benefits

(i) **Defined Contribution Plan**

The benefit in the form of contribution to the Statutory Provident Fund, Employee State Insurance and Employee Labour Welfare Fund etc. are considered as the defined contribution plans and are recognized on the basis of the amount paid or payable for the period during which services are rendered by the employees.

(ii) **Gratuity : Defined Benefit Plan**

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump sum payment to vested employees on retirement, death while in employment or on termination of employment. Vesting occurs upon completion of five years of service. The Company makes annual contribution to the gratuity fund established as Trust. The Company accounts for the liability for gratuity benefits payable in future based on actuarial valuation conducted by an independent actuary on projected unit credit method as at the Balance Sheet Date.

Long term employee benefits

(i) **Leave Encashment**

The employees of the Company are entitled to the compensated absences and leave encashment as per the policy of the Company, the liability in respect of which is provided, based on an actuarial valuation conducted by an independent actuary on projected unit credit method as at the Balance Sheet date. Actuarial gains and losses comprise experience adjustments and the effects of changes in actuarial assumptions are recognized immediately in the Revenue Account and Profit and Loss Account as income or expense.

(ii) **Long Term Incentive Plan and Special Assured Bonus Plan**

Long Term Incentive and special assured bonus payable to employees is provided based on actuarial valuation including actuarial gains/losses at the Balance Sheet date. The actuarial valuation has been carried out using the Projected Unit credit Method.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)

IRDA Registration number 148 dated 26 April, 2012



4.13. Employee Stock Option Scheme("ESOS")

The Company follows the intrinsic method for computing the compensation cost, for options granted under the scheme(s). The difference if any, between the fair value and the grant price, being the compensation cost is recognized as deferred stock option expense and is charged to Revenue Account and Profit and Loss Account on straight line basis over the vesting period of options.

4.14. Taxation

a. Current Tax

Current income tax, assets and liabilities are measured at the amount expected to be paid to or recovered from the taxation authorities in accordance with the tax regime inserted by Taxation Laws (Amendment) Act, 2019 in the Income Tax Act, 1961 and the Income Computation and Disclosure Standards (ICDS) enacted in India by using tax rates and the tax laws that are enacted at the reporting date.

b. Deferred Tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the Balance Sheet date. Deferred tax assets and liabilities are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

4.15. Earnings per share

The basic earnings per share is calculated by dividing the Net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the reporting period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Care Health Insurance Limited

(Formerly Known as Religare Health Insurance Company Limited)
IRDA Registration number 148 dated 26 April, 2012



4.16. Foreign Currency Transactions

Transactions denominated in foreign currencies are recorded at the rates prevailing on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the closing rate of exchange at the year-end. The gains/losses on account of restatement and settlement are recognised in the Revenue Account and / or Profit and Loss Account.

4.17. Provisions and Contingencies

A provision is recognized when an enterprise has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.

Contingent losses arising from claims other than insurance claims, litigation, assessment, fines, penalties, etc. are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. A disclosure for a contingent liability other than those under policies is made when there is a possible obligation or a present obligation that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are neither recognized nor disclosed in the financial statements.

4.18. Receipts & Payments Account

- (i) Receipts and Payments Account is prepared and reported using the Direct Method, in conformity with Para 2.2 of the Master Circular on Preparation of Financial Statements - General Insurance Business dated October 5, 2012, issued by the IRDAI.
- (ii) Cash and cash equivalents comprise cash including cheques in hand, bank balances and demand deposits (other than investment related fixed deposits with Banks).

4.19 Goods and Service Tax liability on insurance service is set-off against the input tax credits available from tax paid on input services. Unutilized credits, if any, are carried forward for set-off in future. GST Paid for input services where input tax credit is not available is recognized in Revenue Account and / or Profit and Loss Account.

Schedules forming part of financial statements

NOTES FORMING PART OF ACCOUNTS

1	Contingent Liabilities	(₹ '000)	
Particulars	As at 31.03.2022	As at 31.03.2021	
Partly paid up Investments	-	-	
Claims, other than against Policies, not acknowledged as debts by the Company	-	9,825	
Underwriting commitments outstanding (in respect of shares and securities)	-	-	
Guarantees given by or on behalf of the Company	9,395	9,395	
Statutory demands / liabilities in dispute, not provided for (Refer Note 1)	-	-	
Reinsurance obligations to the extent not provided for in accounts	-	-	
Others - Against the cases filed by the ex landlord, Vendor and Ex employee	-	5,672	

Note 1

The above disclosure does not include demands of Rs. 338,808 thousands (PY Rs.182,195 thousands) raised by income tax authorities for AY 2017-18 and 2018-19. Against the additions made in the assessment orders, the company has filed appeals before the Commissioner of Income Tax (Appeals). Also, rectification application seeking credit of brought forward tax losses has been filed against the demands raised.

Since the company in earlier assessment years (AY 2013-14 to 2015-16) has got favorable orders from appellate authority in similar matters, the company is confident that the orders of CIT(A) will be in company's favor for these assessment years as well. In the opinion of the company, the said demands are not sustainable and hence no provision is considered necessary in books.

2	Basis used by the Actuary for determining provision required for IBNR / IBNER
	'Claims Incurred But Not Reported' (IBNR) and Claims Incurred But Not Enough Reported (IBNER) as at March 31, 2022 has been estimated by the Appointed Actuary in compliance with the guidelines issued by IRDA and applicable provisions of professional guidance notes issued by the Institute of Actuaries of India.

3	Encumbrances
	All the assets of the Company are free from any encumbrances except deposits in banks amounting to ₹ 9,395 thousands (previous year ₹ 9,395 thousand). These deposits have been placed with banks for the purposes of executing bank guarantees. The Company has all assets within India.

4	Estimated Amount of Commitments made and Outstanding for	(₹ '000)	
Particulars	As at 31.03.2022	As at 31.03.2021	
Loans	-	-	
Investments	-	-	
Fixed Assets (Net of advances)	49,128	17,368	

5	Claims less Reinsurance paid to Claimants*	(₹ '000)	
Particulars	As at 31.03.2022	As at 31.03.2021	
In India	14,435,513	7,984,333	
Outside India	100,066	109,621	

* Excluding Claims paid on Reinsurance accepted

6	Age-wise Breakup of Gross Claims Outstanding*	(₹ '000)	
Particulars	As at 31.03.2022	As at 31.03.2021	
Outstanding for more than six months	-	-	
Others	4,512,086	3,326,771	
	4,512,086	3,326,771	

*Excluding IBNR provisions, amounts payable to service providers and third party administrator.

7	Claims settled and remaining unpaid for more than six months is NIL (Previous year : NIL)				
8	(a) Premium less Reinsurance Written During the Year				(₹ '000)
Class of Business	In India		Outside India		
	For the Year ended 31.03.2022	For the Year ended 31.03.2021	For the Year ended 31.03.2022	For the Year ended 31.03.2021	
Miscellaneous	30,884,225	19,808,292	-	-	

(b) No premium income is recognized on "Varying Risk Pattern" basis.

Schedules forming part of financial statements

9 **Extent of Risk Retained and Reinsured** (₹ '000)

Class of Business	Risk Retained		Risk Reinsured	
	For the Year ended	For the Year ended	For the Year ended	For the Year ended
	31.03.2022	31.03.2021	31.03.2022	31.03.2021
Miscellaneous	78%	77%	22%	23%

10 **Value of Contracts in relation to Investments** (₹ '000)

Particulars	As at	As at
	31.03.2022	31.03.2021
Purchase where deliveries are pending	-	-
Sales where payments are overdue	-	-

11 All the investments are made in accordance with Insurance Act, 1938 and IRDA (Investment) Regulations, 2016 and are performing assets.

12 The Company does not have any investment property as at March 31, 2022 or March 31, 2021.

13 Historical cost of investments which are valued at Fair Value

(₹ '000)

Particulars	March 31, 2022		March 31, 2021	
	Reported / fair value	Historical Cost	Reported / fair value	Historical Cost
Mutual Funds	1,667,040	1,662,611	1,361,244	1,358,446
Equity Shares	769,867	778,894	15,415	35,252

14 Statement showing the Age-wise Analysis of the Unclaimed Amount of the Policyholders as on 31st March 2022

(₹ in Lakhs)

Particulars	Total Amount	Age-wise Analysis							
		0-6 months	7-12 months	13-18 months	19-24 months	25-30 months	31-36 months	37-120 months	More than 120 months
Claims settled but not paid to the policyholders / insured due to any reasons except under litigation from the insured /policyholders	-	-	-	-	-	-	-	-	-
Sum due to the insured /policyholders on maturity or otherwise	-	-	-	-	-	-	-	-	-
Excess collection of the premium / tax or any other charges which is refundable to the policyholders either as terms of conditions of the policy or as per law or as may be directed by the Authority but not refunded so far*	18	15	2	0	0	0	-	-	-
Cheques issued but not encashed by the policyholder/insured *	357	85	53	34	35	20	22	107	-

* Fair Value of Investments against unclaimed amount is ₹ 387 Lakhs

Details of Unclaimed amounts and investment income thereon

(₹ in Lakhs)

Particulars	FY 2021-22		FY 2020-21		
	Policy Dues	Income Accrued	Policy Dues	Income Accrued	
Opening Balance	223	26	191	27	218
Add: Amount Transferred to unclaimed amount	285	-	163	-	163
Add: Cheques issued out of the unclaimed amount but not encashed by the policyholders	31	-	4	-	4
Add: Investment income on unclaimed fund	-	11	-	8	8
Less: Amount paid during the year	195	6	135	9	144
Less: Amount transfer to SCWF (Net of claims paid in respect of amount transferred earlier)	-	-	-	-	-
Closing Balance of Unclaimed Amount	344	31	223	26	249

15 Segment Information

a) Business Segments

The Company's primary reportable segments are identified in accordance with the Insurance Regulatory and Development Authority (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations 2002. The operating expenses and investment and other income have been allocated to various segments as per accounting policies disclosed above. However, due to the nature of the business, segment assets and liabilities have been allocated to various segments to the extent possible.

(₹ '000)

Segment	Health		Personal Accident		Other	
	As at 31.03.2022	As at 31.03.2021	As at 31.03.2022	As at 31.03.2021	As at 31.03.2022	As at 31.03.2021
Health Segment						
Segmental Revenue	34,920,304	23,383,132	3,894,564	2,256,974	659,491	240,113
Segmental Result	(1,455,236)	(400,942)	1,216,756	577,441	(118,968)	48,796
Segmental Liabilities						
Claims Outstanding (Net)	4,414,605	3,098,499	565,724	492,688	382,793	247,621
Unexpired risk reserve (Net)	13,177,832	8,303,157	1,819,368	1,046,421	171,381	43,202
Premium Deficiency Reserve	-	1,297,581	-	61,202	-	-
Premium received in advance	1,830,679	515,436	133,866	46,517	65,203	10,033
Segment Assets						
Outstanding Premium (Net of Provision)	-	-	-	-	-	-

b) Geographical Segment

There is no reportable Geographical Segmentation for the year.

Schedules forming part of financial statements

16 Details of Managerial Remuneration as per terms of appointment are as under:

Particulars	(₹ '000)	
	Year ended 31.03.2022	Year ended 31.03.2021
Salaries & Allowances	28,057	28,062
Contribution to Provident and other funds	1,582	1,582
Total **	29,638	29,644

**The managerial remuneration paid to Mr. Anuj Gulati, the Managing Director and Chief Executive officer of the company is in accordance with the approval accorded by the Insurance Regulatory and Development Authority as per the requirement of Sec 34A of the Insurance Act, 1938. Pursuant to the said approval ₹ 15,000 thousand (Previous year ₹ 15,000 thousand) is charged to Revenue Account, and remaining ₹ 14,638 thousand (Previous year ₹ 14,644 thousand) is charged to Profit and Loss Account.

Provision towards gratuity and leave encashment of MD & CEO of the company amounting to ₹ 687 thousands (Previous Year ₹ 1,081 thousands) are determined actuarially and same has been charged to Profit & Loss account.

During the year a provision of ₹ 29,656 thousand (Previous Year ₹ 29,656 thousand) towards bonus for managerial personnel has been created. The same is payable subject to approval by shareholders and Insurance Regulatory and Development Authority. The Provision has been charged to Profit and Loss account.

During the year bonus of ₹ 5,448 thousand has been paid to Mr. Anuj Gulati, the Managing Director and Chief Executive Officer of the Company. The said bonus has been paid out of previous year provisions.

Perquisites are calculated as per Income Tax Rules, 1962.

Above figures does not included perquisites calculated on exercise on equity stock options.

17 The results of reinsurance inward are accounted as per last available statement of accounts/confirmation from ceding insurers.

18 Operating Lease Commitments

The Company has taken on lease office premises. Lease payments on cancellable and non cancellable lease of ₹ 196,984 thousand (previous year ₹ 162,695 thousand) are charged to Revenue Account. The future minimum lease payments in respect of non cancellable leases as at the balance sheet date are as under:

Particulars	(₹ '000)	
	As at 31.03.2022	As at 31.03.2021
Payable not later than one year	70,220	59,546
Payable later than one year but not later than five years	50,171	31,238
Payable later than five years	-	-
Total	120,391	90,784

19 Disclosure required under section 22 of Micro, Small and Medium Enterprise Development Act, 2006

Particulars	(₹ '000)	
	As at 31.03.2022	As at 31.03.2021
i. Principal amount and interest due thereon remaining unpaid to any supplier covered under MSMED Act.	25,768	10,892
ii. Amount of interest paid by the Company in terms of Section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year.	632	-
iii. The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act.	-	-
iv. The amount of interest accrued and remaining unpaid	1	-
v. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of MSMED Act, 2006	-	-
Total	26,401	10,892

The above information regarding dues to Micro, Small and Medium Enterprises has been determined to the extent such parties have been identified on the basis of information collected with the Company.

Schedules forming part of financial statements

20

Detailed list of Related parties

S.No	Nature of Relationship	Name of party
1	Holding Company	Religare Enterprises Limited
2	Subsidiaries of immediate Holding Company	Religare Finvest Limited
		Religare Capital Markets Limited
		Religare Broking Limited
		Religare Insurance Limited
		Religare Global Asset Management Inc.
		Religare Credit Advisor Private Limited
		Religare Comtrade Limited
3	Subsidiaries of fellow Subsidiaries	Religare Care Foundation (Section 8 Company) (w.e.f 04th February, 2022)
		Religare Housing Development Finance Corporation Limited
		Religare Commodities Limited
		Religare Capital Markets International (Mauritius) Limited
		Religare Capital Markets (Europe) Limited
		Religare Capital Markets (UK) Limited
		Religare Capital Markets Corporate Finance Pte Limited
		Religare Capital Markets Inc.
		Religare Capital Markets (Hong kong) Ltd.
		Tobler (UK) Limited
		Kyte Management Limited
		Religare Capital Markets (Singapore) Pte Limited
		Bartleet Religare Securities (Private) Limited
		Bartleet Asset Management (Private) Limited
		Strategic Research Limited
		Bartleet Wealth Management (Private) Limited
Religare Advisors Limited		
Religare Business Solutions Limited		
4	Individuals owning, directly or indirectly, interest in the voting power that gives them control	Nil
5	Key management personnels	Mr. Anuj Gulati
		Mr. Pankaj Gupta
		Mr. Ajay Shah
		Mr. Chandrakant Mishra
		Mr. Nitin Katyal
		Mr. Anoop Singh
		Ms. Bhawana Jain
		Mr. Manish Dodeja
		Mr. Pratik Kapoor
		Mr. Sanjeev Meghani
Mr. Irvinder Singh Kohli		
6	Enterprises over which Key Management Personnel / Relatives thereof are having Significant Influence	Nil

21 Summary of significant related party transactions

(₹ '000)					
S. No	Name of the Related Party	Nature of Relationship with the Company	Description of Transactions / Categories	As at 31st March, 2022 / For the year ended 31st March, 2022	As at 31st Mar 2021 / For the year ended 31st Mar 2021
1	Religare Enterprises Limited	Holding Company	Reimbursement of Expense	11,230	20,7
			Receipt/Refund of Premium	974	-
			Purchase/Sale of Fixed Assets	-	3
			Payable	479	2,6
			Premium Received in Advance / Cash Deposit	5	-
2	Religare Finvest Limited	Fellow Subsidiary	Receipt/Refund of Premium	5,883	-
			Recovery of Expense	21	-
			Premium Received in Advance / Cash Deposit	243	-
3	Religare Broking Limited	Fellow Subsidiary	Reimbursement of Expense	1	-
			Commission Payable	2,430	1,5
			Commission Expenses	14,308	12,2
			Premium Received in Advance / Cash Deposit	547	-
			Receipt/Refund of Premium	17,701	(5
4	Religare Housing Development Finance Corporation Limited	Subsidiary of Fellow Subsidiary	Receipt/Refund of Premium	6,315	-
			Premium Received in Advance / Cash Deposit	48	-
			Recovery of Expense	22	-
5	Mr. Anuj Gulati/Mr. Pankaj Gupta/ Mr. Ajay Shah/ Mr. Chandrakant Mishra/ Mr. Nitin Katyal/ Mr Anoop Singh/ Ms. Bhawna Jain/Mr. Manish Dodeja/Mr.Pratik Kapoor/Mr.Sanjeev Meghani/Mr. Irvinder Singh Kohli	Key Management Personnel	Remuneration	158,388	192,5
			Receipt/Refund of Premium from KMP	130	1
			Claims Payment to KMP's	6	-
			Allotment of Equity Shares under ESOP/Right Issue	1,235,029	265,0

Notes:

- 1 In case claims paid as per the policy term to person other than insured has not been considered for related party disclosure.
- 2 Premium is net of refund/receipt.
- 3 Above figures does not included perquisites calculated on exercise on equity stock options by KMPs.

22 Code on Social Security

The Indian Parliament had approved the Code on Social Security, 2020 which could impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft Rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stake holders which are under active consideration by the Ministry. The Company will complete its evaluation once the Rules are notified and will give appropriate impact in the financial statements in the period in which the Code and related Rules becomes effective. The implementation of the said code has been postponed by the Government of India as on date.

Schedules forming part of financial statements

23 Employee Benefits

A. Gratuity and Leave Encashment

The following tables summarize the components of the net employee benefit expenses recognized in the Revenue Account and Profit and Loss Account, the fund status and amount recognized in the balance sheet for the gratuity and leave encashment, and give the disclosure relating to actuarial valuation of leave encashment and gratuity liability.

Disclosures relating to actuarial valuation of Leave encashment and gratuity liability:

		Leave Encashment		Gratuity	
		2021-22	2020-21	2021-22	2020-21
I	Assumptions				
	Mortality	Indian Assured Lives Mortality (2012-14) Ult*	Indian Assured Lives Mortality (2012-14) Ult*	Indian Assured Lives Mortality (2012-14) Ult*	Indian Assured Lives Mortality (2012-14) Ult*
	Discount Rate	4.85%	4.50%	4.85%	4.50%
	Rate of increase in compensation	6.00%	6.00%	6.00%	6.00%
	Rate of return(expected) on plan assets	NA	NA	4.85%	4.50%
	Withdrawal rates	18-35: 65% p.a., 36-45: 45% p.a., 46 and above: 25% p.a. and for CEO & + 10%	18-35: 65% p.a., 36-45: 45% p.a., 46 and above: 25% p.a. and for CEO & + 10%	18-35: 65% p.a., 36-45: 45% p.a., 46 and above: 25% p.a. and for CEO & + 10%	18-35: 65% p.a., 36-45: 45% p.a., 46 and above: 25% p.a. and for CEO & + 10%
	Expected average remaining working lives of employees	1.99	1.99	1.99	1.99
II	Changes in present value of obligations				
	DBO at beginning of year	66,120	55,640	157,534	121,733
	Interest Cost	2,707	2,603	6,779	6,018
	Current Service Cost	18,463	17,031	27,492	23,716
	Benefits Paid	(11,927)	(8,205)	(13,753)	(5,117)
	Actuarial gain/(loss) on obligation	(3,456)	949	(25,310)	(11,183)
	DBO at end of year	78,819	66,120	203,362	157,534
III	Changes in fair value of plan assets				
	Fair Value of Plan Assets at beginning of year			144,183	66,886
	Expected Return of Plan Assets			6,479	4,633
	Contributions made	N.A	N.A	13,351	54,847
	Benefits paid			(13,753)	(5,117)
	Actuarial gain / (loss) on plan assets			9,388	22,933
	Fair Value of Plan Assets at end of year			159,648	144,183
				-	-
IV	Fair Value of Plan Assets				
	Fair Value of Plan Assets at beginning of year	-	-	144,183	66,886
	Actual Return of plan assets	-	-	15,867	27,566
	Contributions made	-	-	13,351	54,847
	Benefit paid	-	-	(13,753)	(5,117)
	Fair Value of Plan Assets at end of year	-	-	159,648	144,183
V	Actuarial Gain/(loss) Recognised				
	Actuarial Gain/(loss) for the year (Obligation)	(3,456)	949	(25,310)	(11,183)
	Actuarial Gain/(loss) for the year (Plan Assets)	N.A	N.A	9,388	22,933
	Total Gain/(Loss) for the year	(3,456)	949	(15,922)	11,750
	Actuarial Gain/(loss) Recognised for the year	(3,456)	949	(15,922)	11,750
	Unrecognised Actuarial Gain /(Loss) at the end of year	NIL	NIL	NIL	NIL
VI	Amounts to be recognised in the balance sheet				
	DBO at the end of year	78,819	66,120	203,362	157,534
	Fair Value of Plan Assets at end of year	N.A	N.A	159,648	144,183
	Funded Status deficit/(surplus)	78,819	66,120	43,714	13,351
	Unrecognised Actuarial Gain /(Loss)	NIL	NIL	NIL	NIL
	Net (Asset)/Liability recognised in the balance sheet	78,819	66,120	43,714	13,351
VII	Expense Recognised				
	Current Service Cost	18,463	17,031	27,492	23,716
	Interest Cost	2,707	2,603	6,779	6,018
	Expected Return on Plan Assets	N.A	N.A	(6,479)	(4,633)
	Net Actuarial Loss / (Gain) recognised for the year	3,456	(949)	15,922	(11,750)
	Expense recognised in the statement of P&L A/c	24,626	18,685	43,714	13,351
VIII	Movements in the liability recognised in Balance Sheet				
	Opening Net Liability	66,120	55,640	13,351	54,847
	Expenses as above	24,626	18,685	43,714	13,351
	Benefits paid/Contribution made	(11,927)	(8,205)	(13,351)	(54,847)
	Closing Net Liability	78,819	66,120	43,714	13,351
IX	Current liability	35,863	29,433	43,714	13,351
	Non current liability	42,956	36,687	-	-
	Closing Net Liability	78,819	66,120	43,714	13,351

Schedules forming part of financial statements

Employee's Benefits – Gratuity Experience Adjustment

(₹ '00)

	31.03.2018	31.03.2019	31.03.2020	31.03.2021	31.03.2022
Benefit obligation	54,781	81,133	121,733	157,534	203,311
Fair Value of Plan Assets	37,548	54,658	66,886	144,183	159,611
Funded Status Deficit / (Surplus)	17,233	26,475	54,847	13,351	43,700
Experience Adjustment on plan liabilities (loss)	(10,901)	(16,593)	(19,519)	(9,127)	(26,511)
% of plan liabilities	-19.90%	-20.45%	-16.03%	-5.79%	-13.21%
Experience Adjustment on plan Assets (loss)	1,385	2,611	(12,884)	22,933	9,311
% of plan Assets	3.69%	4.78%	-19.26%	15.91%	5.83%
Actuarial Gain / Loss due to change in Assumptions	604	(196)	(4,423)	(2,055)	(1,611)

Employee's Benefits – Leave Encashment Experience Adjustment

(₹ '00)

	31.03.2018	31.03.2019	31.03.2020	31.03.2021	31.03.2022
Benefit obligation	49,029	52,024	55,640	66,120	78,811
Fair Value of Plan Assets	-	-	-	-	-
Funded Status Deficit / (Surplus)	49,029	52,024	55,640	66,120	78,811
Experience Adjustment on plan liabilities (loss)	(18,481)	(8,361)	1,029	1,741	(4,011)
% of plan liabilities	-37.69%	-16.07%	1.85%	2.63%	-5.08%
Experience Adjustment on plan Assets (loss)	NA	NA	NA	NA	NA
% of plan Assets	NA	NA	NA	NA	NA
Actuarial Gain / (Loss) due to change in Assumptions	428	(104)	(1,841)	(792)	611

B Defined Contribution Plan

The Company's employees are covered by Statutory Provident Fund, Statutory Pension Fund, Employee State Insurance and Employee Labour Welfare Fund to which the Company makes a defined contribution measured as fixed percentage of Salary. During the year amount of ₹ 271,268 thousand (Previous Year ₹ 199,834 thousands) has been charged to Revenue or Profit and Loss Account towards contribution to above schemes/benefits.

24 Deferred Tax

In the presence of the profits during the current and the earlier years/s and certainty of availability of future taxable income, the Company recognized Deferred Tax Assets of Rs.399,527 thousands (net of Deferred Tax Liability of Rs.26,839 thousands) during the current year as detailed below:

	As at 31.03.2022	As at 31.03.2021
Deferred tax assets	(₹ '000)	(₹ '000)
Expenditure covered by section 43B of Income-tax Act, 1961	34,647	43,470
Provision for doubtful trade receivables	21,688	21,688
Provisions including unexpired risk reserve	161,843	392,447
Carried forward unabsorbed depreciation and business loss	208,187	-
Total Deferred tax assets (A)	426,366	457,605
Deferred tax liabilities		
Excess of depreciation/amortization of fixed assets under income-tax law over depreciation/amortization provided in accounts	(26,839)	(36,005)
Total Deferred tax liability (B)	(26,839)	(36,005)
Net Deferred tax asset (liability) = (A-B)	399,527	421,600
Net Deferred tax asset recognized in books of accounts	399,527	421,600

25 Earnings Per Share

Basic earnings per equity share have been computed by dividing net profit (loss) after tax by the weighted average number of equity shares outstanding for the year.

	Particulars	Units	Year ended 31.03.2022	Year ended 31.03.2021
a	Net profit/(loss) after tax	₹ In '000s	114,930	1,022,290
b	Weighted average of number of equity shares used in computing basic earnings per share	No. of Shares in '000s	861,078	812,401
c	Basic earnings per share (a/b)	₹	0.13	1.26
d	Weighted average of number of potential equity shares	No. of Shares in '000s	2,202	10,837
e	Diluted earnings per share [a/(b+d)]		0.13	1.24

*For the purpose of calculating weighted average number of potential equity shares, valuation report as on 31st October 2021 has been considered.

Schedules forming part of financial statements

26 Expenses of Management

The company has charged expenses of ₹ 3,186,972 thousands (Previous year ₹ 2,402,144) to Profit and Loss account, being amount in excess of limits prescribed in Schedule I of Insurance Regulatory and Development Authority of India (Expenses of Management of Insurers transacting General or Health Insurance business) Regulations, 2016. Company has made an application to the Authority seeking forbearance from meeting the prescribed limit of Expenses of Management for 5 years i.e. from FY 2021-22 to FY 2025-26. The same is under Authority's kind consideration. Vide authority's letter dated 5th April 2022, company has got forbearance from meeting the prescribed limit of Expenses of Management for FY 2020-21.

27 Sector Wise Business

Disclosure of Sector wise business based on Gross Direct Written Premium (GWP) as per Insurance Regulatory and Development Authority (Obligations of Insurers to Rural or Social Sectors) Regulations 2015 is as under:

Business Sector	Year ended 31.03.2022					
	GDP (₹ '000s)	No. of Lives	No. of Policies	% of GDP	% of No. of Lives	% of No. of policies
Rural	5,251,030	8,670,956	260,868	13.53%	41.72%	14.63%
Social	744,380	5,898,339	35	1.92%	28.38%	0.00%
Total	38,809,056	20,784,651	1,783,636	100.00%	100.00%	100.00%

Business Sector	Year ended 31.03.2021					
	GDP (₹ '000s)	No. of Lives	No. of Policies	% of GDP	% of No. of Lives	% of No. of policies
Rural	3,128,998	6,217,530	186,024	12.22%	49.84%	13.51%
Social	315,932	5,038,164	29	1.23%	40.38%	0.00%
Total	25,597,536	12,475,977	1,376,812	100.00%	100.00%	100.00%

28 The amount of foreign exchange (loss)/gain booked in Profit and Loss account is (5,028) thousands [Previous year (10,094) thousands].

29 Premium Deficiency Reserve

The outbreak of Covid-19 pandemic has created economic disruption throughout the world including India. The Company has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of these financial statements, as at the date of approval of these financial statements. The Company expects to recover the carrying amount of all its assets including investments in its ordinary course of business. In accordance with IRDAI Assets Liability and Solvency Margin Regulations, 2016, Premium Deficiency Reserve (PDR) is to be maintained at insurer level. Further, with the increasing pace of inoculation amongst the population and other efforts by the government/medical organizations which may likely to help mitigate some of the adverse impact of COVID-19 on the expected claims. It was also observed that the growth of business is significantly better in current financial years, as compared to previous financial year leading to higher proportion of UPR available for future claims. Based on the above, the Appointed Actuary has advised to maintain NIL Premium Deficiency Reserve (PDR) as on 31st March 2022. As certified by the Appointed Actuary the assumptions used for such estimation are appropriate (based on available information) and method for estimation of PDR is in accordance with the requirements of the IRDAI.

30 Actuarial valuation of claims where claims period exceeds four years

Currently the Company has not underwritten any policy, where the claim payment term exceeds 4 years. Hence, no actuarial valuation is required.

31 Share Capital

Authorized share capital of the company as on 31st March, 2022 is ₹ 1,300 crores. The Company has allotted ₹ 67.53 crores worth of equity shares (face value Rs. 10) during the year.

32 Penal Actions Details by Various Government Authorities

IRDA circular no 005/IRDA/F&A/CIR/MAY-09 requires disclosure as per given format in respect of penal actions taken by various Government Authorities.

S.No. Authority	(₹ in Lacs)			
	Non-Compliance/ Violation	Penalty Awarded	Penalty Paid	Penalty Waived/ Reduced
1 Insurance Regulatory and Development Authority	-	-	-	-
2 Goods and Service Tax Authorities	-	-	-	-
3 Income Tax Authorities*	-	-	-	-
4 Any Other Tax Authorities	-	-	-	-
5 Enforcement Directorate / Adjudicating Authority / Tribunal or any Authority under FEMA	-	-	-	-
6 Registrar of Companies/ NCLT/ CLB/ Department of Corporate Affairs or any Authority under Companies Act, 2013	-	-	-	-
7 Penalty awarded by any Court/ tribunal for any matter including claim settlement but excluding Compensation	-	-	-	-
8 Securities and Exchange Board of India	-	-	-	-
9 Competition Commission of India	-	-	-	-
10 Any other Central/State/local Government/Statutory Authority	-	-	-	-

Schedules forming part of financial statements

33 Summary of Financial Statements:

S.No.	Particulars	2021-22	2020-21	2019-20	2018-19	2017-18
(₹ in Lacs)						
OPERATING RESULTS						
1	Gross Direct Premium	388,091	255,975	240,901	184,327	111,078
2	Net Earned Premium Income	251,084	172,947	150,845	109,120	67,967
3	Income from Investments (net)	13,225	10,595	9,673	7,398	4,375
4	Other Income	-	-	-	-	-
5	Total Income	264,309	183,542	160,518	116,518	72,343
6	Commission (Net) - Including Brokerage	11,017	2,661	(2,217)	(3,142)	(4,132)
7	Operating Expenses	107,080	72,104	66,064	53,208	43,408
8	Net Incurred Claims	163,373	95,382	89,194	60,267	35,321
9	Premium Deficiency	(13,588)	11,142	2,446	-	-
10	Change in Unexpired Risk Reserve	57,758	25,136	11,757	17,455	14,220
11	Operating Profit/Loss *	(3,573)	2,253	5,032	6,185	(2,255)
NON-OPERATING RESULTS						
12	Total Income under Shareholders Account	5,128	5,296	1,557	(493)	629
13	Profit /(loss) before tax	1,555	7,549	6,589	5,692	(1,625)
14	Provision for Tax (Net of Mat Credit)	405	(2,674)	24	-	-
15	Profit/(Loss) after tax	1,150	10,223	6,565	5,692	(1,625)
Miscellaneous						
16	Policyholder's Account:					
	a) Total funds	246,044	172,517	123,405	102,322	66,879
	b) Total Investments					
	c) Yield on Investments	6.7%	7.3%	8.2%	8.3%	8.1%
17	Shareholder's Account:					
	a) Total funds	110,564	90,984	54,168	27,844	25,913
	b) Total Investments					
	c) Yield on Investments	6.1%	6.8%	6.4%	7.8%	8.0%
18	Paid Up Equity Capital	90,857	84,104	72,795	68,855	59,483
19	Net Worth	120,737	103,886	58,788	44,133	27,670
20	Total Assets(Net)	389,729	291,726	200,040	157,138	109,934
21	Yield on total investments	6.6%	6.8%	7.8%	8.1%	8.2%
22	Earning Per Share (₹)	0.13	1.26	0.93	0.87	(0.30)
23	Book value per Share (₹)	13.29	12.35	8.04	6.39	4.64
24	Total Dividend	-	-	-	-	-
25	Dividend Per share	-	-	-	-	-

* Does not include amounts transferred from shareholder's account

Schedules forming part of financial statements

34 Employee Stock Option Plan (ESOP)

Details of ESOPs that existed during the financial year

Employee Stock Option Scheme 2010

Series	Date of grant	Number Granted	Maximum term of options granted	Vesting Conditions	Exercise Price per option	Estimated fair value of share granted
Series-I	29-Dec-10	1,856,250	9 years from the date of vesting	20% on expiry of 12 months from grant date	10	10
Series-II	14-Mar-11	12,368,750		20% on expiry of 24 months from grant date		
Series-III	5-Aug-11	1,300,000		20% on expiry of 36 months from grant date 40% on expiry of 48 months from grant date		

Employee Stock Option Scheme 2014

Series	Date of grant	Number Granted	Maximum term of options granted	Vesting Period	Exercise Price per option	Estimated fair value of share granted
Series-I	28-Jul-14	9,575,000	9 years from the date of vesting	33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date	10.00	10.00
Series-II	27-Apr-15	7,780,000				
Series-III	4-Jul-15	1,983,500				
Series-IV	30-Sep-15	3,111,500				
Series-V	30-Nov-15	2,892,550				
Series-VI	2-Feb-16	2,224,080				
Series-VII	30-Mar-16	1,498,150				
Series-VIII	30-Jun-16	1,843,200				
Series-IX	3-Mar-17	633,600				
Series-X	31-Mar-17	861,120				
Series-XI	31-Jul-18	4,061,707				
Series-I	6-Nov-18	28,868,288	9 years from the date of vesting	33.33% on expiry of 12 months from grant date 33.33% on expiry of 24 months from grant date 33.34% on expiry of 36 months from grant date	21.85	21.85
Series-II	6-Nov-18	17,361,155			10.00	21.85
Series-III	7-Feb-19	243,160			10.00	26.10
Series-IV	28-Jun-19	584,584			34.31	34.31
Series-V	19-Nov-19	2,311,376			10.00	34.31
Series-VI	19-Nov-19	657,979			34.31	34.31
Series-VII - New	14-Aug-20	7,397,825			37.89	37.89
Series-VIII*	17-Jan-22	27,758,288		1st vesting - 33.33% Upon completion of: (a) 1 (one) year from the date of grant; and (b) 1 (one) year from date on which the primary issue of minimum INR 250 Crores is completed by the Company ("Vesting Commencement Date") 2nd vesting - 33.33% Upon completion of: (a) 2 (two) years from the date of grant; and (b) 2 (two) years from the Vesting Commencement Date 3rd Vesting - Earlier of: (a) 5 (five) years from the grant date of the Options to the REL Employee; or (b) the Listing.	45.32	45.32

* Options pertains to Religare Enterprises Limited Employees and portion of these Options is subject to IRDAI approval

CEO Scheme 2014

Series	Date of grant	Number Granted	Maximum term of option granted	Vesting Conditions	Exercise Price per option	Estimated fair value of share granted
Category-1 (in lieu of surrender of Options granted under 2010 Scheme)	28-Jul-14	2,000,000	9 years from the date of vesting	100% on expiry of 12 months from grant date	10.00	10.00
Category-1 (new Grant)	28-Jul-14	2,285,714		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	28-Jul-14	1,331,250		100% on expiry of 12 months from grant date		
Category-3	28-Jul-14	7,500,000		31 Mar'16		
Category-1 (new Grant)	27-Apr-15	1,714,286		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	27-Apr-15	668,750		100% on expiry of 12 months from grant date		
Category-3	27-Apr-15	4,500,000		April 27, 2016		
Category-1 (new Grant)	4-Jul-15	428,571		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	4-Jul-15	-		100% on expiry of 12 months from grant date		
Category-3	4-Jul-15	857,143		July 4, 2016		
Category-1 (new Grant)	30-Sep-15	428,571		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	30-Sep-15	-		100% on expiry of 12 months from grant date		
Category-3	30-Sep-15	857,143		September 30, 2016		
Category-1 (new Grant)	30-Nov-15	428,571		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	30-Nov-15	-		100% on expiry of 12 months from grant date		
Category-3	30-Nov-15	857,143		November 30, 2016		
Category-1 (new Grant)	2-Feb-16	428,571		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	2-Feb-16	-		100% on expiry of 12 months from grant date		
Category-3	2-Feb-16	857,143		February 2, 2017		
Category-1 (new Grant)	30-Mar-16	428,571		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2***	30-Mar-16	714,285		100% on expiry of 12 months from grant date		
Category-3	30-Mar-16	857,143		March 30, 2017		
Category-1 (new Grant)	30-Jun-16	407,143		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	30-Jun-16	-		100% on expiry of 12 months from grant date		
Category-3	30-Jun-16	814,286		June 30, 2017		
Category-1 (new Grant)	3-Mar-17	162,297		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	3-Mar-17	-		100% on expiry of 12 months from grant date		
Category-3	3-Mar-17	324,593		March 30, 2018		
Category-1 (new Grant)	31-Mar-17	245,145		33% on expiry of 12 months from grant date 33% on expiry of 24 months from grant date 34% on expiry of 36 months from grant date		
Category-2	31-Mar-17	271,529	100% on expiry of 12 months from grant date			
Category-3	31-Mar-17	490,291	March 31, 2018			
Category-1 (new Grant)	31-Jul-18	471,130	100% on expiry of 12 months from grant date	10.00	21.85	
Category-2	31-Jul-18	157,043				
Category-3	31-Jul-18	942,259				
Series-I	6-Nov-18	13,224,900	33.33% on expiry of 12 months from grant date	21.85	21.85	
Series-II	6-Nov-18	15,561,816	33.33% on expiry of 24 months from grant date	10.00	21.85	
Series-III	7-Feb-19	224,463	33.34% on expiry of 36 months from grant date	10.00	26.10	
Series-IV	28-Jun-19	539,618	33.33% on expiry of 12 months from grant date	34.31	34.31	
Series-V	19-Nov-19	2,162,040	33.33% on expiry of 24 months from grant date	34.31	34.31	
Series-VI - New	13-Jul-20	3,509,002	33.34% on expiry of 36 months from grant date			
Series-VII - New	13-Jul-20	7,015,898	November 6, 2021	37.89	37.89	
Series-VIII - New	13-Jul-20	16,633,239	100% on expiry of 12 months from grant date	37.89	37.89	
Series-IX - New	14-Aug-20	6,710,402	33.33% on expiry of 12 months from grant date	37.89	37.89	
			33.33% on expiry of 24 months from grant date			
			33.34% on expiry of 36 months from grant date			

Note 1: All the grants mentioned above to be settled in equity only.

Schedules forming part of financial statements

Summary of Status of Company's ESOP Schemes

Particulars	As at 31.03.2022	As at 31.03.2021
Number of Options Outstanding at the beginning of the Financial year	101,281,423	103,992,716
Add: Issued During the financial year	27,758,288	41,266,366
Less: Cancellation of Options due to resignations / surrender 2021-22	63,165	10,752,512
Less: Options Exercised during the year	67,525,540	33,225,147
Options outstanding at the end of year	61,451,006	101,281,423
Exercisable at the end of the financial year	11,223,468	34,438,163

For options outstanding, the exercise price ranges between Rs.10 to Rs.45.32 and weighted average remaining contractual life of these grants ranges between 8 to 14 years.

The weighted average price of options exercised during the year ended on 31st March, 2022 is Rs.22.68

Key Assumptions used to estimate the fair market value of options granted during the financial year 2021-22 are as below:

The fair value of equity shares of the company for the purpose of computing compensation cost of ESOP's. has been calculated by taking weighted average of fair values arrived at by using income approach methodology and market approach methodology.

The Company follows the intrinsic method for computing the compensation cost, for options granted under the scheme(s). The difference between the fair value and the grant price, being the compensation cost is recognized as deferred stock option expense and is charged to Revenue Account and Profit and Loss Account on straight line basis over the vesting period of options.

Had the Company followed fair value method based on Black-Scholes model valuing its options, compensation cost for the year ended would have been higher by Rs. 195,916 thousand (March 31, 2021: Rs. 306,678 thousand) and the profit after tax would have been lower by Rs.146,609 thousand (March 31, 2021: Rs. 164,902 thousand) and the Company's basic and diluted earnings per share would have been Rs. -0.04 (March 31, 2021: Rs. 1.06) and Rs. -0.04 (March 31, 2021: Rs. 1.04) respectively.

35 **Corporate Social Responsibility:**

During the year ended March 31, 2022 the Company has incurred expenditure towards CSR activities which are as below:

- (a) Gross amount required to be spent by the company during the year was Rs.13,214 thousands (after adjusting Rs.6 thousands excess spent in previous year); [previous year: Rs. 7,103 thousands]
(b) Amount approved by the Board to be spent during the year Rs. Rs.13,214 thousands (previous year: Rs. 7,103 thousands)

(Rs. in 000's)

Particulars	For the Year ended 31.03.2022	For the Year ended 31.03.2021
(i) Construction/acquisition of any asset	-	-
(ii) On purposes other than (i) above		
(a) Production of a film to build awareness for the COVID-19 inoculation program as well media costs to televise the same	-	7,111
(b) Renovation, upgradation and maintenance of primary school in Nandgaon, Dist. Mathura, Uttar Pradesh	4,884	-
(c) Renovation, upgradation and maintenance of Prem Mahavidyalaya, Mathura, Uttar Pradesh	77	-

Details of ongoing projects and total amount transferred to Unspent CSR Account as per Section 135(6)

Opening Balance		Amount required to be spent during the year	Amount spent during the year		Closing Balance	
With Company	Separate CSR Unspent A/c		From Company's bank A/c	From Separate CSR Unspent Account	With Company	In Separate CSR Unspent Account
-	-	13,214	4,961	-	-	8,253

Note: The unspent amount will be transferred to unspent CSR account within 30 days from the end of the financial year, in accordance with the Companies Act, 2013 read with the CSR Amendment Rules.

Schedules forming part of financial statements

36 Accounting Ratios prescribed by the IRDA

Performance Ratios	2021-22 (In Times / %)	2020-21 (In Times / %)
Gross Premium Growth Rate - Health	48%	7%
Gross Premium Growth Rate - PA	73%	44%
Gross Premium Growth Rate - Travel	175%	-70%
Gross Premium Growth Rate - Total	52%	7%
Gross Direct Premium to Net Worth	3.21	2.46
Growth Rate of Net Worth	16%	77%
Net Retention Ratio - Health	76%	75%
Net Retention Ratio - PA	94%	94%
Net Retention Ratio - Travel	86%	83%
Net Retention ratio - Total	78%	77%
Net Commission ratio - Health	2%	0%
Net Commission ratio - PA	13%	14%
Net Commission ratio - Travel	12%	12%
Net Commission Ratio - Total	4%	1%
Expenses of Management to Gross Direct Premium	40%	42%
Expenses of Management to Net Written Premium	38%	38%
Net Incurred claims to Net Earned Premium	65%	55%
Combined Ratio	103%	93%
Technical Reserves to Net Premium Ratio	0.66	0.74
Underwriting Balance Ratios	-7%	-5%
Operating Profit Ratio	-1%	1%
Liquid Assets to Liability Ratio	0.33	0.30
Net Earning Ratio	0%	4%
Return on Net Worth	1%	7%
Available Solvency Margin (ASM) to Required Solvency Margin (RSM) ratio	1.85	2.45
NPA Ratio	NA	NA

37 Following Expense has been booked for various activities being carried out by Statutory auditors
(₹ '000)

Particulars	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
Statutory Audit Fees	3,800	3,500
Tax Audit & Certification	970	1,090
Out of Pocket Expenses	225	32
Total	4,995	4,622

Schedules forming part of financial statements

- 38 Reinsurance ceded premium in Treaties with Net Premium rate (Net of Commission and Expense) is calculated by applying risk proportion on gross written premium. Difference between treaty rate and rate as arrived by applying risk proportion is recognised as Reinsurance Commission.
- 39 **Provision for Free Look period**
The provision for free look period is duly certified by the appointed actuary
- 40 **Fair Value Change Account**
Fair Value Change Account represents unrealized gains or losses due to change in fair value of listed equity shares and mutual fund units outstanding at the close of the year.
- 41 **Allocation of Investment Income**
Investment income is recognized in Profit & Loss Account and Revenue account based on income generated against investments representing securities in policyholder and shareholder's fund.
- 42 **Disclosure of Fire and Marine Revenue accounts:**
As the Company operates in single insurance business class viz. Health Insurance Business, the reporting requirements as prescribed by IRDA with respect to presentation of Fire and Marine Insurance revenue accounts are not applicable.
- 43 The figures have been rounded off to the nearest thousand, and the Previous year's figures have been regrouped / reclassified in the respective schedules and notes, wherever necessary to conform to the current year's classifications.
- 44 **Basis of Amortization of Debt Securities**
Accretion of discount and amortization of premium relating to debt securities is recognized over the holding/maturity period on a straight line basis and is recognized in the Revenue or Profit & Loss Account.
- 45 There is no other additional material information required to be disclosed pursuant to the provisions of the Companies Act 2013, The Insurance Act 1938, the insurance Regulatory and Development Authority Act 1999 and applicable regulation / circular / Orders etc.

For T.R. Chadha & Co. LLP
Chartered Accountants
Firm Regn No. : 006711N/NS00028

For S.P. Chopra & Co.
Chartered Accountants
Firm Regn No. : 000346N

For and on behalf of Board of Directors

Dr. Rashmi Saluja
Non-Executive Chairperson
(DIN 01715298)

Anuj Gulati
Managing Director & CEO
(DIN 00278955)

Hitesh Garg
Partner
Membership No. :502955

Gautam Bhutani
Partner
Membership No. : 524485

Shamsher Singh Mehta
Non-Executive
Independent Director
(DIN 02201929)

Pankaj Gupta
Chief Financial Officer

Place: Gurugram
Date: 26th April, 2022

Pratik Kapoor
Company Secretary

Amrish Jindal
Head-Finance & Accounts

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

Management Report

In accordance with the provisions of the Insurance Regulatory and Development Authority (IRDA) (Preparation of Financial Statements and Auditor's Report of Insurance Companies) Regulations, 2002 (the Regulation) Management Report is submitted for the year ended 31st March 2022 :

1. Section 3A of the Insurance Act, 1938 has been amended by the Insurance Laws (Amendment) Act, 2015 to remove the process of annual renewal of the Certificate of Registration issued to Insurers under Section 3 of the Insurance Act, 1938 (amended by the Insurance Laws (Amendment) Act, 2015). However, it has been stated that Insurers shall continue to pay such annual fee as may be prescribed by the Regulations. Insurance Regulatory Development Authority of India ("IRDAI") in line with the above amendment issued a general circular stating that Certificate of Registration of the Insurers renewed in 2014, expiring in March 2015, shall continue to be in force from April 1, 2015 subject to payment of renewal fee. It is confirmed that renewal fees for FY 2022-23 has been paid.
2. It is certified that all the dues payable to the statutory authorities up to 31st March 2022 have been duly paid.
3. It is confirmed that the shareholding pattern during the year ended 31st March 2022 is in accordance with the statutory and regulatory requirements.
4. It is hereby declared that management has not directly or indirectly invested outside India the funds of the holders of policies issued in India.
5. The Company is maintaining the Control Level of Solvency as required under the Insurance Act, 1938 (amended by the Insurance Laws (Amendment) Act, 2015) and the relevant Regulation as prescribed by the IRDAI.
6. It is certified that the values of all the assets have been reviewed on the date of Balance Sheet and in management's belief, the assets set forth in the Balance sheet are shown in the aggregate at amounts not exceeding their realizable or market value under the heading – "Loans", "Investments", (wherever applicable) "Agents Balances", "Outstanding Premiums", "Interest, Dividend and Rents Outstanding", "Interest", "Dividends and Rents accruing but not due", "Amounts due from other persons or Bodies carrying on insurance business", "Sundry Debtors", "Bills Receivable", "Cash" and several items specified under "other Accounts".
7. The Investment Risk is managed by creating a portfolio of different asset classes and of varied maturities so as to spread the risk across a wide category of Investee companies. The Company has constituted an Investment Committee, which acts as the policy making body for the Investment operations. The Investment Committee lays down various internal policies and norms governing the functioning of the Investment Department. The Investment Committee periodically discusses the Investment strategy, portfolio structures, performance of the portfolio and related issues. The Investment policy is reviewed regularly in order to align the same with the Company business plans.

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

8. It is confirmed that there were no operations of the Company outside India during the year ended 31st March 2022.

9. Ageing of claims outstanding and trends in settlement of claims are given below:-

a) Details of Claims Outstanding during the preceding five years

Period	2021-22		2020-21		2019-20		2018-19		2017-18	
	No. of Claims	₹ in Lakhs	No. of Claims	₹ in Lakhs	No. of Claims	₹ in Lakhs	No. of Claims	₹ in Lakhs	No. of Claims	₹ in Lakhs
30 Days	13,415	17,274	8,996	9,713	4,825	6,576	1,458	3,842	2,327	2,302
30 Days to 6 Months	4,685	4,380	6,101	8,920	2,599	2,846	3,477	4,035	2,517	2,487
6 Months to 1 Year	-	-	-	-	844	1,544	658	1,249	121	197
1 Year to 5 Years	-	-	-	-	-	-	-	-	-	-
5 Years and Above	-	-	-	-	-	-	-	-	-	-
Total	18,100	21,655	15,097	18,634	8,268	10,966	5,593	9,126	4,965	4,985

Note:

- All Cashless Claims Outstanding are shown in settled as the Customer has already availed the service and the payment will be done to the hospital according to the terms of the Agreement, reimbursement are part of above summary report.
- Amount excluding IBNR provisions, amounts payable to third party administrators.

b) Details of Average Claim Settlement time for the preceding five years

	2021-22		2020-21		2019-20		2018-19		2017-18	
	No. of claims settled	Average time	No. of claims settled	Average time	No. of claims settled	Average time	No. of claims settled	Average time	No. of claims settled	Average time
Cashless (Approved)	329,852	01 Hour 35 Min	202,739	01 Hour 40 Min	891,951	01 Hour 25 Min	567,548	01 Hour 50 Min	182,050	02 Hour
Reimbursement (Settled)	201,700	06 Days	89,020	06 Days	91,697	05 Days	81,065	06 Days	42,833	09 Days
Total	531,552		291,759		983,648		648,613		224,883	

Note: All Cashless Claims Outstanding are shown in settled as the Customer has already availed the service and the payment will be done to the hospital according to the terms of the Agreement.

10. As at 31st March 2022, the investments of the Company are mainly in Debt Securities, Bank Deposits, equity shares and Mutual Funds. As per the IRDA guidelines, all debt securities are considered as held to maturity and valued at historical cost subject to amortization, listed equity shares at market value and

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

Mutual Fund investments are stated at their fair value, being the closing Net Asset Value as at balance sheet date and investments other than those mentioned above are valued at cost. Further, the market value for debt securities as at 31st March 2022 has been calculated as per Fixed Income Money Market & Derivatives Association (FIMMDA) Yield curve and financial benchmark India Pvt. Ltd (FBIL).

11. Investments are in accordance with the Insurance Act, 1938 (amended by the Insurance Laws (Amendment) Act, 2015) and Investment Regulations, 2016. Investment Portfolio consists of Government Securities & State Government Securities (Sovereign Guarantee), Infrastructure Bonds, Housing Sector Bonds, Corporate Bonds, Liquid Mutual Funds, listed/unlisted equity shares and Deposits with various Scheduled Banks. There is no Non Performing Asset as at 31st March 2022.
12. In compliance with corporate governance guidelines for insurers in India 2016, below are disclosures as mandated by guidelines.

a. Financial and operating ratios:

Particulars	For the Year ended 31st March, 2022
Net Incurred Claims to Net Earned Premium ratio	65%
Net commission to Net written premium ratio	4%
Expense of Management to net Written Premium ratio	38%

Note: Ratios are calculated basis formulae described in Master Circular on Preparation of financial statements of General insurance Business dated October 2012

b. Solvency ratio:

	₹ Lakhs
Total Available Solvency Margin (ASM)	114,139
Total Required Solvency Margin (RSM)	61,768
Solvency Ratio (Total ASM/Total RSM)	1.85

Note: Solvency Ratio is calculated basis formulae prescribed in IRDAI (Assets, Liabilities, and Solvency Margin of General Insurance Business) Regulations, 2016

c. Financial performance :

Particulars	For the Year ended 31st March, 2022
Gross Premium Growth Rate	52%
Growth rate of Net Worth	16%
Net worth as on 31 st march 22	120,737 Lakhs

Note: Ratios are calculated basis formulae described in Master Circular on Preparation of financial statements of General insurance Business dated October 2012

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

d. Risk Management architecture

The company has a Board Approved Risk Policy which acts as a framework for the companies Risk Architecture and Framework. There are regular reviews at a Functional level to monitor the Risks defined at each Function/Process and corrective steps are immediately taken. The company has A Risk Committee as a part of its Board Committees which on a quarterly basis reviews the Risk Policy, Effectiveness of the Risk Management System and the Exposure to Key Risks that the company is exposed to.

e. Details of number of claims intimated, disposed off and pending :

Claims Experience	Health	Overseas Travel	Personal Accident	Total
Claims O/S at the beginning of the period	14,149	254	694	15,097
Claims Reported during the period	591,736	17,679	4,577	613,992
Claims Settled during the period	513,384	15,428	2,740	531,552
Claims Repudiated during the period	76,903	834	1,700	79,437
Claims Closed during the period	0	0	0	0
Claims O/S at End of the period *	15,598	1,671	831	18,100
Less than 3 months	15,598	1,671	831	18,100
3 months to 6 months				
6 months to 1 year				
1 year and above				

* All Cashless Claims Outstanding are shown in settled as the Customer has already availed the service and the payment will be done to the hospital according to the terms of the Agreement

f. Elements of remuneration package (including incentives) of MD & CEO and all other Key Management Persons

Particulars	(₹ Lakhs)
	As at 31.03.2022
Salaries & Allowances	1,494
Contribution to Provident and other funds	87
Perquisites	3

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

g. Payments made to group entities from policyholders funds

(₹ Lakhs)

S. No	Name of the Related Party	Nature of Relationship with the Company	Description of Transactions / Categories	As at 31st March 2022
1	Religare Enterprises Limited	Holding Company	Expense Reimbursement to Religare Enterprises Limited	112
2	Religare Broking Limited	Fellow Subsidiary	Commission Expenses	143
			Reimbursement of Expense	0.01

13. Payments made to companies and organizations in which directors are interested* are as under:

Name of the Director	Entity in which Director is interested	Interested As	Nature of Payment	Amount of payment during the financial year (₹ in Lakhs)
NIL				

* As defined under Section 2(76) of Companies Act, 2013 and applicable Rules thereof.

14. The Company has adopted a prudent investment policy with emphasis on optimizing return with minimum risk. Significant weighing of the assets has been made towards low risk investments such as Government Securities, Treasury bills and other good quality Debt instruments. All the investments have been duly serviced.

15. It is hereby confirmed:

- a. That the Financial Statements have been prepared in accordance with generally accepted accounting principles and policies, applicable accounting standards and current practices prevailing in the insurance industry and there are no material departures.

Unearned Premium Reserve (UPR) as per the option granted by IRDAI is being created at 50% of the net written premium of the preceding 12 months since 2017. The Company based on the industry trend, experience gained and based on expert opinion, on the policies where the premium is earned fully during the accounting period (on expired policies), no UPR is created.

Management have made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the operating Profit or Loss of the Company for the year.

- b. That the management has taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the applicable provisions of the Insurance Act 1938 (amended by the Insurance Laws (Amendment) Act, 2015) and Companies Act 2013 (erstwhile Companies Act 1956) for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

Care Health Insurance Limited

IRDA Registration number 148 dated 26 April, 2012

- c. The Authority vide circular under reference IRDA/F&A/CIR/ACTS/023/01/2020 dated January 21, 2020 has notified that the effective date of implementation of Ind AS shall be decided after the finalization of IFRS 17 by International Accounting Standards Board (IASB).
- d. That the management has prepared the financial statements on a going concern basis.
- e. That the management has ensured that the internal audit system is in commensurate with the size and nature of business and is operating effectively.
- f. That the Company has a separate function called Fraud and Risk Investigation, to safeguard the assets for preventing and detecting fraud and other irregularities.

For and on behalf of Board of Directors

Dr. Rashmi Saluja
Non-Executive Chairperson
(DIN 01715298)

Anuj Gulati
Managing Director & CEO
(DIN 00278955)

Shamsher Singh Mehta
Non-Executive
Independent Director
(DIN 02201929)

Pankaj Gupta
Chief Financial Officer

Pratik Kapoor
Company Secretary

Amrish Jindal
Head-Finance & Accounts

Place: Gurugram
Date: 26th April, 2022

To know more, visit our website

www.careinsurance.com

- ✓ Quick quote & buy
- ✓ Online renewals
- ✓ Customer support
- ✓ Claim centre

Scan the QR code to join our
10th anniversary celebration.



REACH US @



Care Health-Customer App



8860402452

Self Help Portal:

www.careinsurance.com/self-help-portal.html

Submit Your Queries/Requests:

www.careinsurance.com/contact-us.html

care HEALTH
INSURANCE

Care Health Insurance Limited

(Formerly Religare Health Insurance Company Limited)

Registered Office: 5th Floor, 19 Charwa House, Nehru Place, New Delhi-110019.

Correspondence Office: Unit No. 604 - 607, 6th Floor, Tower C, Unitech Cyber Park,

Sector-39, Gurugram -122001 (Haryana) CIN: U66000DL2007PLC161503

IRDAI Registration Number - 148.